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Abstract
Building risk models from multiple different sources of data allows researchers to
incorporate the best available information on key model parameters. In this thesis,
we develop and apply methodology for optimally combining information from multiple
data sources in two main contexts.
In the first, motivated by the need for building subtype-specific absolute risk mod-
els for breast cancer, we develop and apply methodology for combining information
information from analytic cohort or case-control studies and from population-based
registries. We address the statistical challenges involved with handling different types
of missing information in this context. We derive variance estimators for the risk pre-
dictions produced by such models, accounting for different sources of uncertainty. We
apply the methods to two large consortia in order to build absolute risk models for
overall breast cancer and for subtypes of breast cancer defined by estrogen receptor
status. We show how the absolute risk models can be used to project distributions
of breast cancer risk for the US population and to evaluate the potential impact of
population-wide modification of breast cancer risk factors.
In the second problem, we consider the issue of how to effectively incorporate ex-
ternal information when building new or updated risk models, again with the goal of
combining data sources to produce models that are more efficient and representative
of the underlying population. In particular, we explore a regression calibration ap-
proach, utilizing a method from sample-survey literature which is traditionally used
for increasing the efficiency of parameter estimation from a given survey by lever-
aging information from external data sources. We examine the performance of the
estimator in a context that has not previously been studied, where the sample and the
ii
external data are representative of different populations. We derive theoretical con-
ditions under which the calibrated estimator produces meaningful estimates, which
are calibrated to the external population, and corroborate our analytic results with
numerical simulations. Our work also identified weaknesses in the methodology and
promising avenues of further research in this important area.
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Absolute risk models predict disease risk in an upcoming time interval based on
known risk factors for an individual or individuals in a population, accounting for the
presence of competing risks (Gail et al., 1989). Absolute risk models for cancers and
other diseases have important clinical and public health applications.
Absolute risk models can be used to identify individuals at high risk of disease in
order to target screening and disease prevention strategies (Jackson, 2000; Jackson
et al., 2005; Pharoah et al., 2008; Gail, 2011). In the past, decisions regarding the
initiation of screening or preventative intervention have often been made on the basis
of age and family history, as proxies for risk. However, there is increasing consensus
in the medical community that these decisions should instead be guided directly by
individualized estimates of risk, which can be obtained from absolute risk models that
include a wider array of environmental and genetic risk factors.
At the public health level, direct estimates of risk allow researchers to quantita-
tively weigh the risks and benefits of a particular screening regime or preventative
intervention and tailor those strategies in a way that is optimal for the underlying
population (Grundy, 1999; Gail, 2001; Murray et al., 2003). An example of this in
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practice is the American Society for Colposcopy and Cervical Pathology Consensus
Guidelines for cervical cancer screening, which are based on quantitative evaluation
of the benefits and potential harms of screening as measured by absolute risk (Saslow
et al., 2012). Other examples include using absolute risk models to identify absolute
risk thresholds for which the benefits associated with preventative breast cancer treat-
ments, such as Tamoxifen, outweigh the risks associated with treatment (Chlebowski
et al., 2002) and to evaluate the impact of smoking cessation on lung cancer (Halpern
et al., 1993). Absolute risk models can also be used to determine the necessary sample
size for prevention trials by projecting the expected distribution of disease risk based
on the distribution of risk factors in a population (Gail, 2011).
At the patient level, absolute risk estimates can be used to counsel individuals
on the basis of their personal risk. In fact, the National Cancer Institute has cre-
ated a number of risk assessment tools for this purpose, which are available online.
The Breast Cancer Risk Assessment Tool estimates a woman’s risk of invasive breast
cancer based on responses to 8 questions about her age, race, and reproductive and
medical history (Gail et al., 1989). The Colorectal Cancer Risk Assessment Tool esti-
mates risk of colorectal cancer for individuals between the ages of 50 and 85 (Freedman
et al., 2009a), and the Radiation Risk Assessment Tool estimates an individual’s life-
time risk of cancer from exposure to ionizing radiation (de Gonzalez et al., 2012).
These examples only represent a small number of the many risk calculators available
online for providing doctors and patients with more personalized estimates of disease
risk. The large number of absolute risk models now directly in use by the public
speaks to a growing trend toward managing one’s health behaviors in the context of
quantitative estimates of disease risk.
In this thesis, we address several methodological issues in developing absolute risk
models, dealing with complexities for combining information from various different
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sources of data. While the methods are developed with the aim of building models for
predicting risk of breast cancer, the methodological issues addressed are applicable
in a wide variety of settings. In the following, we describe the two main motivating
problems and present the challenges involved with each. First, we discuss the objective
of building a subtype-specific absolute risk model for breast cancer by integrating
different data sources and we present key data applications. Second, we introduce
the problem of how to best make use of external information or existing models in
order to calibrate a new risk model more generally.
1.1 Developing Subtype-Specific Absolute Risk
Models for Breast Cancer
Subtype-specific models are particularly relevant for breast cancer as it is a heteroge-
neous disease, encompassing numerous subtypes based on tumor characteristics such
as the presence of hormone receptors or growth factors (Burstein, 2005). Distinct
breast cancer subtypes differ with respect to age of diagnosis, risk factors, prevention
options, treatment regimes, and survival outcomes (Anderson and Matsuno, 2006;
Visvanathan et al., 2009; Putti et al., 2005; Burstein, 2005). Researchers who note
this heterogeneity recommend taking a stratified approach and express hope that
subtype-specific risk prediction may result in better implementation of prevention
strategies and earlier tumor detection (Anderson and Matsuno, 2006; Yang et al.,
2011a). The methods we develop in this thesis are driven by consideration for the
characteristics of real data sources available for building such a model. Specifically,
we consider the utility of existing cohort studies, case-control studies, national disease
registries, and national surveys for fitting a subtype-specific absolute risk model for
breast cancer in the US population.
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Cohorts
To fit a subtype-specific absolute risk model, one needs information on covariate rela-
tive risks, age-specific disease incidence rates, and covariate and subtype distributions
that are representative of the population of interest. In an ideal world, one might
have access to an existing large, representative, prospectively-collected cohort study
which could provide information for each component of the model. However, cohort
studies are expensive to conduct and, especially for rare outcomes such as breast
cancer subtypes, require many years of follow-up in order to accrue a large number of
cases. In practice, the ideal cohort study for a given application may be unavailable
and conducting one may not be feasible or timely. Additionally, a given cohort study
may not be representative of incidence in the population as increased intensity of
screening and follow-up in the study may artificially produce higher rates than would
naturally occur in the population. To mitigate these limitations, we propose methods
that enable the use of existing cohort data in conjunction with other complementary
data sources, such as registries that contribute more representative incidence rates.
Case-Control Studies
For developing a subtype-specific absolute risk model, case-control studies have some
advantages over cohort studies, along with some limitations. Case-control studies
specifically recruit cases with the disease of interest so they require less time to ob-
tain a large number of cases, particularly for rare subtypes, and are generally less
expensive to conduct than cohort studies. Incident case-control studies can provide
representative estimates of the disease subtype distribution, provided the sampled
cases are representative of all cases in the population for whom we intend to estimate
subtype-specific absolute risk. Case-control studies can be used to estimate covariate
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odds ratios, which approximate relative risks for rare diseases such as breast cancer
subtypes.
A drawback of case-control studies is that data on lifestyle factors may be affected
by selection or recall bias, and one must carefully consider whether a given sample
is representative of the underlying population. In particular, a major challenge in
designing case-control studies is ensuring that the sampled controls are representative
of unaffected individuals in the population. It is well known that hospital-based
incident case-control studies are likely to have non-representative controls that are
generally less healthy than the overall population; however, such a study may be an
excellent source of cases with subtype information. We address the issue of how one
can utilize these studies, for which no adequate controls are available, in order to
estimate key components of a subtype-specific absolute risk model.
A further limitation of case-control studies is that they do not provide estimates
of disease incidence due to the fact that specific numbers of cases and controls are
purposefully sought for inclusion in the study. For this reason, one cannot build an
absolute risk model from a case-control study alone, even one with good controls.
Thus, in order to make use of the rich data provided by case-control studies, we
develop methods for combining information with other data sources that can provide
the representative incidence rates and, in some cases, the representative controls that
case-control studies lack.
Registries
National disease registries are an excellent source of incidence rate information for
absolute risk models. A strength of this data is that it is representative of the na-
tional population and typically includes immense sample sizes, which result in very
precise estimates of incidence. However, these large databases generally collect very
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little covariate information, so the reported incidence rates are based on a mixture
of women with different covariate levels. For diseases with established subtypes, na-
tional registries typically collect the necessary disease characteristic information for
delineating subtype-specific incidence rates; however, this is not always the case.
We develop methods for calibrating subtype-specific absolute risk models to na-
tionally representative registry incidence rates, dealing with the situation where the
registry is missing some or all tumor characteristics needed to define the subtypes of
interest. For many diseases, the research community is still learning how to identify
clinically relevent subtypes. In the event that new biomarkers are identified in future
research, these methods will allow researchers to calibrate absolute risk models for the
newly identified subtypes to incidence rates from a registry that has not yet begun
to collect information on the new biomarkers.
Other Challenges
In addition to addressing considerations of study design and missingness, a major
statistical component of this research is the development of methods for variance
estimation that account for the integration of different data sources. Generally, we
approach this problem by applying the functional delta method and concepts from
empirical process theory to derive variance estimators. After working through the
statistical theory, we computationally implement the proposed methods, validate their
performance using simulations, and finally apply them to a real and relevant data
example, that of building a subtype-specific absolute risk model for breast cancer.
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1.2 Applications
In this thesis, we present two major data applications; specifically, we develop ab-
solute risk models for breast cancer in the US population using data from two large
constortia. First, we build an absolute risk model for overall breast cancer using
prospective cohort data from the Breast and Prostate Cancer Cohort Consortium
(BPC3) (Hunter et al., 2005; Husing et al., 2012). In a second data application, we
apply our methods to case-control studies from the Breast Cancer Association Consor-
tium (BCAC) in order to build subtype-specific absolute risk models for breast cancer
subtypes defined by estrogen receptor status (Breast Cancer Association Consortium,
2006; Yang et al., 2011b). In both applications we aim to develop models that are rep-
resentative of the US population. To better accomplish this, we calibrate the models
to nationally representative breast cancer incidence rates from the National Cancer
Institute’s Surveillance Epidemiology and End Results (SEER) database. Much of
our subtype-specific methods development is motivated directly by practical consid-
erations encountered in working with these datasets. In the following, we give a brief
overview of these three influential data sources.
BPC3
The BPC3 includes 8 large, prospective cohorts that together total more than 17,000
cases and 19,000 controls with breast cancer outcomes (Institute, 2014). Specifically,
the consortium includes the following studies conducted in the US population: the
American Cancer Society Cancer Prevention Study-II (CPS-II); Harvard’s Nurses’
Health Study (NHS) and Women’s Health Study (WHS); the National Cancer In-
stitute’s Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial;
the Multiethnic Cohort (MEC); and the Women’s Health Initiative (WHI) (Milne
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et al., 2010; Fasching et al., 2012; Nickels et al., 2013). It also includes cohorts from
Europe and Australia, the European Prospective Investigation of Cancer (EPIC) and
the Melbourne Collaborative Cohort Study (MCCS) respectively. The BPC3 data
includes well known anthropomorphic and reproductive risk factors for breast cancer,
as well as genetic information on 24 single nucleotide polymorphisms (SNPs), which
have been previously shown to be associated with breast cancer.
BCAC
The BCAC includes more than 60 case-control studies from many different countries,
with a total of more than 90,000 breast cancer cases and 90,000 controls. The BCAC
data also includes information on tumor characteristics, including estrogen receptor
(ER) status, progesterone receptor (PR) status, and human epidermal growth factor
receptor 2 (HER2), biomarkers which are frequently used to classify breast cancer
into subtypes. Additionally, the BCAC contains data on standard risk factors for
breast cancer along with genetic information on 77 SNPs previously shown to be
associated with breast cancer. The case-control studies that make up this consortium
include those that are population-based, hospital-based, and family-based, and some
studies that are of mixed design. With so many studies, there is a huge variety in
the magnitude and patterns of missing data, in both the covariates and the tumor
characteristics. In our methodological work, we carefully consider the ramifications
of these practical data issues in the context of building subtype-specific absolute risk
models and discuss statistical approaches to handle those issues.
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SEER
The SEER database monitors cancer incidence in regions across the country covering
approximately 28 percent of US population, roughly 88 million people (Howlader
et al., 2011). For regions covered by the registry, SEER data includes breast cancer
incidence and population rates linked with age, race, sex, registry location, and year
of diagnosis (Howlader et al., 2011). Beginning in 1990, SEER began to collect ER
and PR status on breast cancer cases, and in 2009 began collecting HER2 information
(Fritz and Ries, 1998; Adamo et al., 2011). To be specific, in our data applications
we use age-specific incidence rates for integer ages 0 to 85, for those classified as
white race, from the SEER 18 Research Data, which contains the largest geographic
coverage available in SEER. The age-specific incidence rates were stratified into three
rates according to estrogen receptor status as ER positive, ER negative, and ER
unknown. In applications where only the overall rates of breast cancer were needed,
we simply calculated the age-specific incidence rates for any breast cancer as the sum
of these three rates for each age.
1.3 Calibrating to External Information
As new risk factors are identified, there is a need to update existing risk models to fully
use the most up-to-date information in predicting disease risk. Ideally, such a risk
model should be developed from a large prospective cohort study that is representative
of the underlying population and has information on all risk factors, including both
the existing and the new ones. In practice, however, such studies are hard to come by.
For example, many risk models for cancers and heart diseases have been built using
long-established cohort studies; however, these studies are unlikely to have collected
the information necessary for evaluating new risk factors which have only recently
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been identified.
Rather than conducting an entirely new cohort study to add a few new risk fac-
tors to a given risk model, it is more efficient to incorporate information from existing
models as much as possible. For many diseases, established risk models have already
been developed based on data from large representative cohorts and thoroughly val-
idated in independent studies. Calibrating to this sort of quality information can
result in an updated model that is more representative of the underlying population.
An example of this, which we have discussed previously, is the idea of calibrating
an absolute risk model to national registry data in order to make the model more
nationally representative.
Often, case-control studies are the primary source of information on the new risk
factors, such as genetic markers, with which to update a model. However, we know
that in case-control studies lifestyle factors may be affected by potential selection or
recall bias, making them less than ideal for estimating those effects. In this situation,
one could benefit by taking advantage of an existing published model, which does
have representative information for the existing risk factors that may not be well
measured in a given case-control study.
Even if representative information is available on all risk factors from a single new
study, building the updated model solely based on that study may be inefficient in
that doing so makes no use of the information from published models. If established
models were originally built based on a larger, more representative study and carefully
evaluated through independent validation studies, one ought to leverage information
from those models to develop an updated risk model that is better calibrated to the
underlying population.
In this thesis, a key problem we seek to address is exactly how to best use this
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external data when building a risk model. We explore the use of a “regression calibra-
tion” approach that is popular in the sample-survey community as a tool for increasing
efficiency of parameter estimation from a given survey by utilizing information from
large external data sources on related variables (Wu and Sitter, 2001; Wu, 2003). We
investigate the performance of the estimator both theoretically and numerically, in a
setting to which it has not previously been applied, where the external information
is representative of the population of interest while the sample population may differ
in some respects. We identify conditions under which the calibration estimator is an
effective method for calibrating a new risk model to external information, resulting
in a model that is calibrated to the external population of interest. We also diagnose
some situations where the method does not perform well, and make practical recom-
mendations regarding when the method can be safely applied. Finally, we identify




Methods for Developing Absolute
Risk Models for Disease Subtypes:
Integrating Multiple Data Sources
In this chapter we develop a general framework for modeling the absolute risk of
disease subtypes. We present the model and discuss a number of different ways to
estimate key parameters depending on which data sources are available. We review
the strengths of the different approaches and extend the methods to handle situations
where there is missing data in the tumor characteristics which define the disease
subtypes of interest. Finally, we use empirical process theory to derive variance
estimation procedures that account for multiple sources of uncertainty.
2.1 The Model
Absolute risk is the probability that a specific event will occur within a defined interval
of time, accounting for the risk of competing events. In this thesis we model absolute
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risk where the event of interest is tumor diagnosis. Specifically, we consider the setting
where individuals are at risk of being diagnosed with tumor subtypes j = 1, ..., J
defined by a set of tumor characteristics, h = 1, ..., H. Mathematically speaking, we
model the probability that an individual with covariates Z, who is tumor free at age a,
is diagnosed with a tumor of subtype j∗, within some upcoming time interval τ , given
that the individual is at risk of competing events including other tumor subtypes,
P [a ≤ T < a + τ, j = j∗|T ≥ a, Z]. In the following, we extend the absolute risk
model presented in Gail (2011) to accommodate disease subtypes, building up from
basic probability principles to provide a clear depiction of the framework upon which
the model is based.
The probability of an event in the interval (a, a + τ) is simply the probability of
the event happening at any given time, integrated over the entire interval. Thus we
express
P [a ≤ T < a+ τ, j = j∗|T ≥ a, Z] =
∫ a+τ
a




P [T = t, j = j∗|T ≥ t, Z]P [T ≥ t|Z]
P [T ≥ a|Z]
dt.
We have decomposed the absolute risk probability into an integral over the product of
two standard functions in survival analysis: the survival function, S(t) = P (T ≥ t),
and the subtype specific hazard function, λj∗(t) = P (T = t, j = j
∗|T ≥ t) (Kalbfleisch
and Prentice, 1980). We leverage the classic relationships between these quantities
(namely S(t) = exp(−Λ(t)) and Λ(t) =
∫ t
0
λ(t) ) to further manipulate the expression
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of the absolute risk






















λ(t|Z) is the overall hazard function for any event, including diagnosis of any tumor
subtype, as well as competing events. Thus, if we denote the hazard for competing







relationship allows us to express the absolute risk solely in terms of the subtype
specific hazard functions λj and the hazard of competing mortality














Thus far we have not made any modeling assumptions; we have simply worked with
standard relationships in probability to express the absolute risk of subtype j∗ in terms
of subtype specific hazard functions. At this point, we incorporate a Cox proportional
hazards model for the subtype specific hazard functions, λj(t|Z) = λ0j(t)eZβj for
j = 1, ..., J where λ0j(t) is the baseline hazard function, or the hazard function for an
individual with referent level covariates. We also assume that competing mortality
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risks do not depend on covariates other than age. These modeling choices result in
















This is our primary subtype specific absolute risk model of interest. Later we will
discuss situations where one might choose to incorporate additional modeling assump-
tions, but in each case we will use this model as a starting point.
2.1.1 Model Parameters
Fitting this subtype-specific absolute risk model requires estimation of:
1. the hazard rate of competing mortality events c(t)
2. the hazard ratio parameter for each subtype β1, ..., βJ , and
3. the baseline hazard function for each subtype λ01(t), ..., λ0J(t).
We allow these functions to be as flexible as possible by parametrizing the baseline
hazard functions and the competing hazard function non-parametrically, assigning a
parameter to each time point where we have data with which to estimate the value
of the function. We expand on the details in Section 2.3.
Depending on the available data sources, one can estimate these quantities in a
number of different ways. For instance, estimates of the hazard rate of competing
mortality events c(t) can be obtained empirically from a representative cohort study
with mortality data or given by the age-specific mortality rates provided by a national
survey, such as the US National Vital Statistics System. In the following sections, we
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discuss a variety of methods for fitting the final two key pieces of the model, starting
with the Cox hazard ratio parameters for each subtype.
2.2 Estimating Subtype-Specific Hazard Ratios
In this section, we discuss methods for estimating the subtype-specific Cox hazard
ratio parameters from cohort and case-control studies. The exponentiated parame-
ters, eβj , are subtype-specific hazard ratios. We present options for estimating the
βj parameters in the case where there is missing data in the tumor characteristics
variables that define each subtype.
2.2.1 Estimating Hazard Ratios from Cohort Data
Suppose we have data from a cohort study that prospectively follows individuals until
they die, are censored, or are diagnosed with a tumor. Specifically, suppose data is
collected on (Z, T, S) where Z denotes multivariate covariate data, T the time to the
observed event and S the type of event, with S = 1, ..., J for the tumor subtypes and
S = 0 for death or censoring.
Methods are well established for estimating Cox model hazard ratio parameters
from time to event data collected by cohort studies (Kalbfleisch and Prentice, 1980).
However, in the absolute risk setting, the different tumor subtypes act as competing
risks for one another. The standard method for estimating a particular βj∗ in the
presence of competing risks was developed by Holt and expanded on by Prentice
in 1978. The method is based on a partial likelihood that conditions on subtype.
Specifically, the partial likelihood is constructed from the probability that individual
i fails at time t(i), conditioning on the risk set at that time (Rt(i) = l : tl ≥ t(i)) and
the fact that exactly one failure of type j∗ occurs at that time. The partial likelihood
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is the product of this probability for all individuals (i) who experienced the event of





















(Holt, 1978; Prentice et al., 1978). (2.2)
Conditioning on subtype is useful because the baseline hazard functions cancel out,
resulting in a partial likelihood and corresponding score function that only involve















 = 0. (2.3)
Iterative methods are used to obtain the estimate β̂j that solves this equation.
Alternatively, one can estimate β∗j from a partial likelihood that does not condition
on subtype. This unconditional partial likelihood is based on the probability that
individual i fails at t(i) given the risk set at time t(i) and that exactly one failure
occurs at that time, regardless of the subtype (Kalbfleisch and Prentice, 1980). For
each time of an observed event t(i), this probability can be expressed in terms of the
overall hazard function as the partial likelihood








The overall hazard of failure λ(t(i)|zi) is comprised of the sum of subtype-specific
hazards, where “subtype” S = 0 captures the competing non-tumor events. In-
corporating the subtype-specific proportional hazards model results in the following
expression for the partial likelihood,





















































Unlike in the score function for the conditional partial likelihood given by equation
(2.3), the score function given by equation (2.4) involves the βj parameters and the
baseline hazard functions λ0j(t) for all subtypes. This makes parameter estimation
slightly more computational in that we must successively update each parameter,
plugging in current best versions of the other parameters (including the many param-
eters defining the non-parametric baseline hazard function), in order to iteratively
obtain final estimates. However, we show in Appendix A that if we plug-in a non-
parametric estimate of hazard into the unconditional partial likelihood score equation
and assume no tied failure times, this equation simplifies to the score equation from
the conditional partial likelihood. Thus, under a non-parametric model for baseline
hazard, β̂j is equivalent to β̃j. If we were to incorporate a parametric model for
baseline hazard, we would expect increased efficiency in the estimate of β̃j due to the
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fact that the unconditional partial likelihood approach, PL′ (β1, ..., βJ), does not lose
information by conditioning.
2.2.2 Estimating Hazard Ratios from Case-Control Data
Appropriate cohort data is not always available and when this is the case another op-
tion is to estimate the subtype-specific hazard ratio parameters βj from case-control
data. For rare outcomes, case-control studies are typically more economical in pro-
viding a greater number of cases, especially when particular subtypes are of interest.
Prentice and Breslow (1978) show how to estimate hazard ratio parameters β from a
Cox proportional hazards model using case-control data, and they extend discussion
of the method to the competing risk context. The authors demonstrate that the con-
ditional likelihood for β from a retrospective sampling scheme, conditioning on the
numbers of cases and controls selected, is the same as the likelihood for prospective
data associated with the Cox model (Prentice and Breslow, 1978). Having established
this link, they describe a computational strategy for estimating β through standard
logistic regression that has the form
log
{
P [S = j|T = t, z]
P [S = 0|T = t, z]
}
=α(t) + zβ.
Effectively, the authors show that one can estimate Cox hazard ratio parameters β
by simply fitting a logistic regression model that includes a non-parametric function
of time, α(t). In practice, this can be accomplished by including categorical age
strata in the model. Logistic regression is standard in statistical software packages,
so implementing this method is straightforward. We can apply this method to obtain
subtype-specific hazard ratio parameters βj from case-control data simply by fitting
separate logistic regression models for each of the J subtypes.
19
However, rather than modeling each of the subtype outcomes individually, we
propose extending the ideas of Prentice and Breslow (1978) to multinomial logistic
regression and instead model the risk of each subtype simultaneously. This is a
standard way to model categorical outcomes and it is well known that multinomial
logistic regression produces more efficient parameter estimates than individual logistic
regression models that estimate the same parameters (Agresti, 2002).
Additionally, because multinomial logistic regression estimates all parameters si-
multaneously, in certain situations it is possible to fit a multinomial model using
data that would necessarily be excluded when fitting a logistic regression model. In
section 2.2.3, we describe instances where this is the case and demonstrate how to
reparametrize the multinomial model in order to make use of this data.
2.2.3 The Multinomial Likelihood
Several data features of the Breast Cancer Association Consortium (BCAC) moti-
vated us to develop and apply a reparametrized multinomial logistic regression model
in order to estimate the hazard ratios for subtypes. Our first consideration focused
on how to handle data from the numerous hospital-based studies in the consortium.
While the hospital-based case-control studies provided a representative sample of
cases from the population, the hospital-based controls did not constitute a represen-
tative sample of non-cases in the population. Thus, for the purposes of the analysis,
the hospital-based case-control studies could only contribute the representative case
data, with the non-representative controls excluded. Additionally, due to the fact
that the BCAC data is made up of multiple studies, we needed to estimate covariate
hazard ratios adjusted for study to help ensure that the observed relationships were
not driven by systematic differences in the way data was collected or processed at
different study centers.
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However, for the hospital-based studies contributing cases but not controls, it is
not possible to fit a model that adjusts for study using standard methods. To estimate
the study effect, the estimation procedures in logistic regression and multinomial
logistic regression rely on contrasts between cases and controls within a given study,
so when a study does not have controls, the study effect is not estimable. Excluding
the hospital-based studies entirely would allow use of standard methods, but at the
cost of reduced sample size, less efficient parameter estimation, and a colossal waste
of data.
Hospital-based studies with cases of different subtypes have information on case-
case hazard ratios. If we were to fit logistic regression models for each subtype
separately, there would be no way to incorporate that information. However, because
multinomial logistic regression estimates parameters for all subtypes simultaneously,
in principle it should be possible for hospital-based cases to contribute case-case
information to the estimation, with population-based studies that have representative
controls contributing to estimation of the case-control parameters. To achieve this
we needed to reparametrize the multinomial model.
In the following section, we show how to reparametrize the multinomial logistic
regression model in order to include data from studies that are missing controls while
appropriately adjusting for study effects. We go on to extend the method to allow
cases with incomplete subtype information to contribute to estimation of the model
parameters. While the development of this model is motivated by issues encountered
in the BCAC data, the reparametrized model should be useful for addressing similar
issues that may arise in other datasets as well.
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Notation
For data (Zl, Sl) on individuals l = 1, ..., N , let Zl denote a vector of covariates and let
Sl denote an integer disease status, taking values Sl = 0 for controls and Sl = 1, ..., J
mutually exclusive disease subtypes.
A standard multinomial logistic model for this data takes the form
log(
P (S = j|Z)
P (S = 0|Z)
) = Zβj (2.5)
for j = 1, ..., J , where βj is a parameter vector. Standard methods obtain parameter




















However, this multinomial likelihood is currently defined such that the controls are
the referent outcome category. As discussed, under this parametrization it is not
possible to estimate study effects for the studies that do not have controls.
Assume for now that the studies without controls have cases of all subtypes j =
1, ..., J . Data from these studies can be used to estimate
log
(
P (S = j∗|Z)




P (S = j∗|Z)
P (S = 0|Z)
/
P (S = j′|Z)
P (S = 0|Z)
)
= Z(β∗j − β′j)
for any j∗, j′ ∈ 1, ..., J . Thus, while studies without controls cannot contribute di-
rectly to the estimation of the βj parameters, data from these studies can contribute
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to estimation of the contrasts βj∗ − βj′ for j∗, j′ ∈ 1, ..., J .
Reparametrizing the Likelihood
To leverage this idea in the likelihood, consider the data into two parts (Zi, Si) and
(Zk, Sk), with observations from studies with controls indexed by i = 1, ..., Ni and
those from studies without controls indexed by k = 1, ..., Nk. We know that there
are no controls in (Zk, Sk), so we construct the likelihood conditional on the fact that


















Again incorporating the multinomial model given by equation (2.5), we express the


























As previously discussed, in this likelihood the studies without controls contribute to
estimation of βj − β1. To use this in practice, all that remains is to implement a
Newton-Raphson algorithm to optimize the likelihood with respect to βj. This could
be done from the existing likelihood directly, but our preference is to reparametrize
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exp(Zi (θj + θ1))
1 + exp(Ziθ1) +
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j=2







exp(Zi (θj∗ + θ1))
1 + exp(Ziθ1) +
J∑
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exp(Zi (θj + θ1))
1 + exp(Ziθ1) +
J∑
j=2
exp(Zi (θj + θ1))
P2j∗i =
exp(Zi (θj∗ + θ1))
1 + exp(Ziθ1) +
J∑
j=2








Getting Back Estimable Parameters
Converting maximum likelihood estimates θ̂ back into the original parametrization is
straightforward, with β̂1 = θ̂1 and β̂j = θ̂j + θ̂1 for j = 2, ..., J . This can be accom-





















However, the parameter vector β includes both covariate effects and study effects, for
subtypes j=1,...,J. As discussed previously, some study effects βj[s] are not estimable
for studies without controls (only the contrasts θj[s] are estimable, which is why we
reparametrized the likelihood as we did). Though we may be able to estimate θj[s],
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that does not change the fact that those elements of βj[s] are not estimable. When we
map the estimates θ̂ back to β̂, we must indicate which elements are not estimable.
In order for a given study effect βj[s∗] to be estimable, the study of interest and the
referent study must both have controls and cases of subtype j. In general, it is not a
hindrance that some study effects are not estimable because in most situations they
are simply nuisance parameters in a model where our primary goal is to estimate
covariate effects. The main purpose of including study in the model is to adjust for
the study effect, which is accomplished under the θj parametrization before map-
ping back to βj. Thus even though study effects cannot be estimated under the βj
parametrization, the final estimable βj estimates are appropriately adjusted for study.
Incorporating Incomplete Information for Classifying Case Subtype
Another feature of the BCAC data that we wanted to handle in developing the
reparametrized multinomial model was missing data in the subtype defining char-
acteristics. For example, we have discussed that breast cancers can be classified into
subtypes based on estrogen receptor (ER) status and progesterone receptor (PR)
status, which define four breast cancer subtypes: ER-PR-, ER-PR+, PR+ER-, and
ER+PR+. In the BCAC data ER status is missing on 19.4% of the cases and PR
status is missing on 30.4%. For cases with missing data on one of the tumor char-
acteristics, only partial information is available for assigning subtype outcome and
multiple different subtypes are possible based on the known information. For exam-
ple, if an individual’s breast cancer is known to be ER+ but the PR status is missing,
then the tumor could be either ER+PR- or ER+PR+, while we know that it is not
ER-PR- or ER-PR+. Though this information is incomplete, it would be wasteful to
exclude the partial information, especially on such a large number of cases. In this
section, we extend the ideas from the previous likelihood to allow individuals with
26
incomplete subtype information to contribute to estimation of the model parameters,
while still accommodating for studies without controls.
In the previous section, we defined the outcome S as a single scalar taking val-
ues 0,1,..., J, depending on that individual’s specific combination of observed disease
characteristics. This implicitly assumed that there was complete information avail-
able on the disease defining characteristics in order to assign each individual’s tumor
to exactly one case subtype. To handle the fact that multiple subtypes are possible
when tumor characteristics are missing, we adapt our notation to define the outcome
as a binary vector Si = [S0, S1, ..., Sj]i according to whether the subtype is a possi-
bility given the known disease defining characteristics. When enough information is
available to define the subtype exactly, the Si vector will only assign one Sji to 1.
In the previous section when we assumed complete subtype information, each Si
only needed to reflect a single known outcome, say j∗. Thus, the likelihood given by
equation (2.7) only needed to reflect P (Si = j
∗|Zi) for each person, given generally as
J∏
j=0
P (Si = j|Zi)
I{Si=j} . However, when there is incomplete information to determine
subtype, the likelihood must account for some individuals whose incomplete tumor
information allows multiple tumor subtypes to be possible, say Si = j
∗ or j′. In this
case, the likelihood should reflect
P (Si = j
∗ or Si = j

















I{Sjk=1}P (Sk = j|Zi, Sk ≥ 1)
)
.
Again we parametrize the likelihood with parameters βj for j = 1, ..., J from the
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These score functions are essentially the same as the score functions for complete
subtype data given by equations (2.8) and (2.9); however, in this formulation an
individual may have more than one non-zero indicator in the outcome vector Si =
[S0, S1, ..., Sj]i if multiple subtypes are possible due to some unknown subtype defining
information. The derivatives of these score functions are the same as those given
previously in equations (2.10), (2.11), and (2.12), resulting in the same expressions for
the Fisher’s information matrix and the same Newton-Raphson estimation procedure
as previously described.
Calculating the Variance




= [ I(θ) ]−1, where I (θ)
is the Fisher’s information matrix based on the derivatives of the score functions
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= A [ I(θ) ]−1A′.
Another way to calculate the variance of θ and β is to use influence functions.
This method of variance calculation is based on expressing
√





independent identically distributed contributions and applying the central limit the-








′ · ψ]. With the appropriate formula for computing ψ which we derive below,
the variance is estimated by the empirical variance of ψm in the data.
In this setting, the primary goal is to estimate covariate effects while adjusting
for study effects. When we compute the influence functions for the covariate effect
parameters, we must take into account the additional variance that arises due to
estimation of the nuisance study effect parameters. If we denote the effects of interest
θp and the nuisance effects θnui, the function that does this is the efficient influence










eff = S(θp)− Eθ [S(θnui)′]Eθnui [S(θnui)S(θnui)′]
−1 Sθnui .
We compute the efficient influence functions empirically using the expressions for the
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Based on the linear relationship between θ and β, once we have the influence functions
ψp(NxP ) for the parameters of interest θp we can easily obtain the influence function for
βp as φp = ψpA
′. The influence functions φp are useful for other variance calculations,
such as computing the variance of a complex function f(β̂p). Specifically, φp will later
be used in a variance calculation for subtype-specific absolute risk estimates that are
based on βj parameters from this reparametrized multinomial model.
Simulations
In order to eventually incorporate this method into our absolute risk model, we im-
plemented the reparametrized multinomial likelihood in R. To verify that the coded
method was functioning well, we evaluated its performance in several simulation set-
tings.
Specifically, we generated cohort data by simulating three predictor variables, dis-
tributed as x1 ∼ N (µ = 0, σ2 = 9), x2 ∼ Bernoulli (p = 0.2), x3 ∼ Bernoulli (p = 0.5),
and randomly assigned individuals to one of three studies. We then generated an
outcome variable y, taking values 0 for controls or 1, 2, 3, 4 for subtypes, from a
multinomial model with known parameters, given in Table 2.1. In this simulation
we considered the four subtypes to be defined by two binary tumor characteristics,
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Table 2.1: True Parameter Values for Multinomial Simulation:
Covariate Log Odds Ratios for Four Subtypes
Subtype 1 Subtype 2 Subtype 3 Subtype 4
βx0 -2 -3 -1 -1
βx1 log(1) log(1.03) log(1.04) log(1.05)
βx2 log(0.75) log(1) log(0.25) log(0.5)
βx3 log(0.6) log(0.6) log(0.95) log(0.7)
ER status and PR status. Accordingly, we generated tumor characteristic variables
ER and PR based on the simulated subtype variable y, with Subtype 1 = ER-PR-,
Subtype 2 = ER-PR+, Subtype 3 = ER+PR-, and Subtype 4 = ER+PR+.
In the first simulation setting, we fit the model with the complete data, with con-
trols in all three studies and complete information on the tumor characteristics. In
the second setting, we removed all controls in the second study to evaluate perfor-
mance in the case where some studies are fully missing controls. In the third setting,
we randomly inserted missing values into the ER and PR variables to examine the
method’s performance when some tumor characteristic information is missing.
In each setting, we generated 500 datasets of sample size 200,000 and used the
multinomial likelihood method to estimate the hazard ratio parameters for each
subtype. We assigned Subtype 4 (ER+PR+) to be the referent subtype in the
reparametrization, both to test our function’s option for user specification of the
referent subtype and to ensure that the most commonly occuring subtype was used
as referent.
Table 2.2 presents the bias as a percentage of the true parameter value for the
log odds ratio estimates from the reparametrized multinomial model for under the
three simulation settings. For parameters with true value equal to zero, we present
the absolute bias instead of the percent bias, which was cannot compute as it would
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Table 2.2: Percent Bias of Reparametrized Multinomial Estimates for Covariate
Log Odds Ratio Parameters of Four Subtypes, for True Values in Table 2.1
Percent Bias
Subtype 1 Subtype 2 Subtype 3 Subtype 4
Complete
Data
βx1 *2.0E-04 -1.3 -0.2 -0.2
βx2 -0.2 *-2.9E-04 0.0 0.0
βx3 0.1 -0.6 -0.4 0.1
No Controls
in Study 2
βx1 *-2.6E-05 -0.2 0.1 0.1
βx2 -0.1 *-9.9E-04 0.1 0.1




βx1 *-7.1E-05 -0.1 -0.2 -0.4
βx2 0.4 *3.8E-04 -0.1 -0.1
βx3 0.0 0.4 0.7 0.0
“ * ” indicates where bias is reported instead of percent bias due to
true values of 0.
involve dividing by zero. The results in Table 2.2 show that the implemented method
provides unbiased parameter estimates in all simulation settings.
Having verified the unbiasedness of the parameter estimates, we next evaluate
the performance of the variance estimators. We will refer to the Fisher’s informa-
tion variance estimator as “model-based” and the variance estimator derived from
the influence functions as “robust.” We compare the standard deviations from these
variance estimators to the average empirical standard deviation in the point estimates
observed for the 500 datasets. In Table 2.3 we present the bias and coverage prob-
ability for the model-based and robust estimates of standard deviation in the three
simulation settings . The results in Table 2.3 show that both the model-based and
robust variance estimators have less than 10% bias in all cases and coverage probabil-
ities consistently at the 95% level. We see a small percentage of bias in the standard
33
Table 2.3: Percent Bias and Coverage Probability of Model-Based and Robust Stan-
dard Deviation Estimates for Covariate Log Odds Ratio Parameters of Four Subtypes
Percent Bias Coverage Probability




βx1 -7.3 -5.2 -3.1 -4.7 0.97 0.97 0.96 0.95
βx2 4.1 1.7 -1.1 -1.5 0.95 0.95 0.96 0.95
βx3 -3.4 0.0 -1.8 1.4 0.97 0.94 0.95 0.94
βx1 -7.3 -5.3 -3.1 -4.7 0.97 0.96 0.96 0.96
Robust βx2 4.1 1.7 -1.1 -1.6 0.95 0.95 0.96 0.95
βx3 -3.4 0.0 -1.9 1.4 0.97 0.94 0.95 0.94
No Controls in Study 2
Model-
Based
βx1 -6.5 -2.2 2.1 -1.1 0.96 0.97 0.94 0.95
βx2 1.7 0.1 -1.1 -1.3 0.94 0.96 0.95 0.95
βx3 -1.0 -1.4 -3.5 4.0 0.96 0.95 0.96 0.93
βx1 -6.6 -2.3 2.1 -1.1 0.96 0.97 0.94 0.95
Robust βx2 1.7 0.1 -1.1 -1.3 0.94 0.96 0.95 0.95
βx3 -1.1 -1.4 -3.5 4.0 0.96 0.95 0.96 0.93
Missing Data in Tumor Characteristics
Model-
Based
βx1 2.6 -2.3 -0.3 -3.5 0.93 0.95 0.95 0.96
βx2 -2.7 0.9 -5.7 1.1 0.96 0.94 0.96 0.96
βx3 -2.9 3.3 0.1 -4.8 0.95 0.94 0.95 0.96
βx1 2.6 -2.3 -0.3 -3.5 0.93 0.96 0.95 0.96
Robust βx2 -2.7 0.8 -5.7 1.1 0.96 0.94 0.96 0.96
βx3 -2.9 3.2 0.1 -4.8 0.95 0.94 0.95 0.96
“Y” indicates subtype
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deviation estimates for the current simulation parameters, with sample size 200,000
and the ‘true values’ of standard deviation computed empirically on 500 datasets;
however, the bias is not systematic. When we compared the model-based standard
deviations to the robust ones, we found that they were essentially equal, differing on
average by less than 0.005 percent. The model is correctly specified, so this concor-
dance is to be expected and provides further verification that our implementation of
the method is working correctly.
We also performed two additional simulations, considering the setting with con-
trols fully missing from one study and missing data in the tumor characteristics, as
well as a setting with complete data that included an interaction between x2 and
x3. The results (not shown) did not differ significantly from the three simulations
presented here.
2.3 Estimating Baseline Hazard Functions
In addition to the subtype-specific hazard ratio, another key component of a subtype-
specific absolute risk model is the baseline hazard function. The subtype-specific
baseline hazard function λ0j(t) captures the probability P [T = t, S = j|T ≥ t, Z0],
over time. At any given time t, this is the chance that an individual is diagnosed
with subtype j given that they have not been diagnosed with any subtype prior to
that time, for an individual with referent level covariates Z0. In the following section,
we present a number of different options for estimating the subtype-specific baseline
hazard function by integrating information from a variety of data sources, including
analytic cohort studies, case-control studies, national surveys, and population-based
cancer registries. We go on to discuss how one can make use of registry data even if
it is lacking detailed subtype and/or covariate information.
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2.3.1 Estimating Baseline Hazard Functions from Cohort Data
We begin by reviewing a standard method for estimating subtype-specific baseline
hazard functions from cohort data. As in Section 2.2.1, suppose there is a cohort
with variables (Z, T, S) where Z denotes multivariate covariate data, T the time to
the observed event and S the type of event, with S = 1, ..., J for the tumor subtypes
and S = 0 for death or censoring. A common way to model the baseline hazard
function λ0j (t) for each subtype is to do so non-parametrically, allowing the function
to be as flexible as possible and driven by the data. Let non-parametric baseline
hazard function for each subtype λ0j (t) be defined by parameters λjq at each time
point tj1 , ..., tjQj where a failure of the given subtype occurred, with zero hazard
between these time points, yielding
λ0j(t) =






λjqI {tjq = t} .
This baseline hazard function can be estimated by obtaining maximum likelihood
estimates for every parameter λjq that defines the function.
In Appendix B, we give the details for constructing the likelihood in terms of
subtype-specific hazard functions, incorporating the proportional hazards model for
each subtype, λj(t) = λ0j(t)e
βjzi , and expressing the baseline hazard function λ0j(t)






























In Appendix B we also derive the score function for each parameter λjq and show
that the maximum likelihood estimator λ̂jq for a specific subtype j













the number of failure events of type j∗ which occur at tj∗q∗ , divided by weighted
contributions for all individuals in the risk set R(tj∗q∗), those who were event free at
tj∗q∗ . This is equivalent to treating all events other than subtype j
∗ as censored and
applying Breslow’s estimator (Breslow, 1972). Consequently, it is straightforward to
utilize existing software packages to estimate the baseline hazard function for each
subtype by appropriately redefining the censoring variable.
Drawing Strength Across Subtypes
Here, we discuss additional modeling assumptions that could be incorporated to draw
strength across all subtypes in the estimation of each subtype-specific baseline hazard
functions. We initially defined the subtype-specific Cox proportional hazards models
as λj(t|Z) = λ0j(t)eZβj , formalizing the assumption that for a given subtype j the
hazard functions for women with different covariate levels are proportional. This
does not make any assumptions about the relationship between the baseline hazard
functions of different subtypes, say λ0j∗(t) and λ0j′(t). However, one could choose to
model the relationship between the baseline hazard functions of different subtypes,
reducing the number of parameters that need to be estimated and leading to gains in
the efficiency and stability of the parameter estimates.
Specifically, one could model λ0j(t) = λ01(t)hj(θj, t), where hj(θj, t) is a parametric
function and h1(θ1, t) = 1. In order to estimate the subtype-specific hazard functions
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based on this model, one need only estimate the reference baseline hazard function
λ01(t) and the parameters θj of the functions hj(θj, t) = 1 for j=2,..., j=J. We derive
the estimators for this general model.
Again, we characterize the reference baseline hazard function λ01(t) by constant
parameters λ1, ..., λQ at all times, t1, ..., tQ, where an event was observed to occur,
with zero hazard in between. Starting with the likelihood from Appendix B, which is
defined in terms of the subtype-specific baseline hazard functions, we incorporate the
new model λj(t) = λ01(t)hj(θj, t)e
βjzi . We then obtain profile likelihood estimates for
λ01(t), by treating hj(θj, t) as fixed. Appendix C contains the mathematical details





















the total number of observed events that occured at that time, d(tq), divided by
weighted contributions from all those at risk at that time. Recall that the numerator
of the baseline hazard estimator for the standard Cox model given in equation (2.15)
only included cases of the particular subtype j∗. In contrast, the numerator of the
baseline hazard estimator given by equation (2.16) includes all events that occur at
tq, allowing the estimator to draw strength across all subtypes. The estimator also
depends on both hj(θj, tj) and βj.
In Appendix D we derive score functions for θj parameters from the general model
hj(θj, t). In the case of the simple model, hj(θj, t) = θj, the score function can be
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where dj∗ is the number of observed events of subtype j
∗ irrespective of the time that
those events occurred. In both the general formulation of hj(θj, t) and the simple
model where hj(θj, t) = θj, the estimates of θ̂j depend on the referent baseline hazard
parameters λq, so it is necessary to iterate between the estimators in order to obtain
final estimates.
2.3.2 Estimating Baseline Hazard Functions from Registry
Data
While cohort studies can be an excellent source of representative, prospective data
from a population, these studies are expensive and usually conducted over long periods
of time. For this reason, when data is needed to fit an absolute risk model for a
particular outcome, an ideal cohort study may not be available and often one must
resort to case-control studies to estimate the subtype-specific hazard ratio parameters,
βj, using the methods discussed in Sections 2.2.2 and 2.2.3. However, case-control
studies cannot be used to estimate the baseline hazard function. In this case, one can
use external registry data to estimate baseline hazard functions.
Even if appropriate cohort data is available, there are compelling reasons to con-
sider using registry data, instead of the cohort data, to estimate the baseline hazard
functions. Data from a national registry could be more representative of a coun-
try’s overall population than a single cohort study, especially if the cohort study was
conducted in a specialized population. Additionally, the typically large sample size
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of registry data can increase efficiency in the estimation of rates, especially for rare
cancer subtypes.
Methods for incorporating registry data to estimate the baseline hazard for a
single disease outcome have been described by Gail et al. (1989). In particular, the
existing methods handle the issue that registries generally collect minimal covariate
information and thus report only the marginal hazard rates, λm(t) = P [T = t|T ≥ t].
These rates quantify the hazard for individuals with a mixture of different covariate
levels, whereas to fit an absolute risk model, an estimate of the hazard function for
individuals with referent level covariates λ0(t) = P [T = t|T ≥ t, Z0] is needed. Gail
et al. (1989) proposed methods that relate these two quantities through a well-known
public health measure, the attributable risk, and used estimates of attributable risk
to reweight the marginal hazard rates in order to obtain baseline hazard rates for a
single subtype outcome.
In this section, we extend the methods of Gail et al. (1989) to the setting of
multiple disease subtypes. First, we describe methods for estimating subtype-specific
attributable risks and present the details for naturally extending the reweighting ap-
proach described above to handle subtypes. We then address an added complexity in
using registry data to estimate baseline hazard rates for disease subtypes: potentially
missing information on the subtype-defining tumor characteristics.
To rievew, Bruzzi et al. (1985) define attributable risk as the fraction of the
total disease experience in the population that would not have occurred if the effect







Applying this definition to subtypes, the attributable risk for a given subtype j at
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a particular time can be expressed as the difference between the subtype-specific
marginal hazard and the subtype-specific hazard for those with baseline covariates as







Following Gail et al. (1989), a simple rearrangement of this equation shows that
the baseline hazard function, λ0j(t), can be obtained from the subtype-specific at-
tributable risk and the marginal hazard function provided by the registry as λ0j(t) =
(1−ARj(t))λmj(t). To make practical use of this relationship, we need to estimate the
subtype-specific absolute risks ARj(t). We will review how to estimate the subtype-
specific attributable risk from cases only and from a sample of the population by
applying the estimators given by Bruzzi et al. (1985) to subtype outcomes.
Bruzzi’s Formula: Estimating Attributable Risk from Cases Only
Bruzzi et al. (1985) showed that as long as we have estimates of the relative risk, we
can estimate the attributable risk from the covariate distribution among the cases
















As before, dj denotes the total number of subtype j cases. As detailed in Section
2.2, the β̂j estimates can be based on either cohort or case-control data. Based on
the estimate in equation (2.17), λ0j(t) relates to λmj(t) through a weighting of the


















The attributable risk link depends only on the distribution of the covariates among
subtype j cases, so any data source with a representative sample of cases can be used
for estimation. For instance, the covariate distribution among subtype j cases can
come from a population-based or hospital-based case-control study, or from a cohort
study. However, for any of these studies, it is important that the data constitute a
sample of subtype j cases that is representative of the population of interest. If the
study is conducted in a special population, this may not be the case and could result
in biased estimates.
Estimating Attributable Risk from a Sample of the Population
Again following Bruzzi et al. (1985), another way to obtain the baseline hazard func-
tion for each subtype is by weighting the marginal hazard estimates according to the
distribution of covariates in the population, rather than just the cases. Starting with
the relationship ARj(t) = 1− λ0j(t)λmj(t) , one can express the marginal hazard for a given
subtype as a mixture of subtype-specific hazards which are conditional on covariates














eβjZP [Z|T ≥ t]
.
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For rare diseases one may assume that the distribution of covariates for individuals
who survive beyond time t is approximately the same as the distribution in the general









This places fewer restrictions on the data sources that can be used to estimate the at-
tributable risk. Aside from estimates of the subtype specific hazard ratio parameters,
β̂j, this calculation depends entirely on estimates of the joint covariate distribution
P̂ [Z], which can be estimated from any sample with covariate data that is representa-
tive of the population of interest, such as a population-based cohort study, a national
survey, or the controls from a population-based case-control study. From these data
sources, ÂRj(t) can be obtained empirically or with further modeling of P [Z].
Putting this together with the relationship λ0j(t) = (1 − ARj(t))λmj(t), the
subtype-specific marginal hazard functions relate to the baseline hazard functions










We have shown how the attributable risk relates the marginal hazard functions pro-
vided by the registry to the baseline hazard functions needed in the model. We
detailed two methods for estimating the attributable risk, using the distribution of
the covariates in a representative sample of cases or of individuals in the population.
Both are valid approaches and the decision for which method to use should depend
on the quality and representativeness of the available data.
Thus far, we have discussed estimates ÂRj and ÃRj which are constant over time.
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A simple but effective way to allow the attributable risk to vary with time is through
a piecewise constant function, with each parameter representing the attributable risk
within a different stratum of age. The same estimators can be applied, restricting
the calculation to covariate data within the appropriate age stratum. In order to
do this, the data sources used to estimate time varying attributable risk must have
information on age.
Registry Data with Missing Tumor Characteristics
In some cases, a registry may not contain all the information necessary to determine
subtype. In the most extreme case, the registry may not contain any information on
subtype and thus only provides only the overall hazard rate of any tumor. In this
situation, it is still possible to estimate baseline hazard functions for the subtypes of
interest calibrated to registry data, by incorporating subtype distribution information
from other data sources.
The overall age specific incidence rate provided by the registry, λm+(t), will re-
flect the hazard for a mixture of subtypes and individuals with different covariate
levels. We must obtain λmj(t), the age-specific incidence function for each subtype
marginalized over the covariates. Once we have λmj(t), we can apply previously
discussed methods that make use of attributable risk to obtain the baseline hazard
λ0j(t).
One approach to get λmj(t) from λm+(t) would be to reparametrize the marginal




for each subtype j = 1, ..., J and model ξj(t). For example, a restrictive model might
make the assumption that the ratio is constant over time, ξj(t) = ξj for each subtype.
One would then estimate ξ̂j =
nj
n+
from any representative sample of incident cases
(an appropriate cohort or incident case-control study), with nj and n+ denoting the
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number of subtype j cases and the total number of cases respectively.
An example of a more flexible model would be a piecewise constant function,
parametrizing ξj(t) = ξjk for selected intervals tk ≤ t ≤ tk+1. One could then estimate
the observed fraction of subtype j cases among all cases, restricted to the age stratum
defined by tk, ξ̂jk =
njk
n+k
, from a representative sample of incident cases with subtype
and age information. One could choose to consider other parametric functions for
ξc(t); however, in most situations the constant or time-varying proportionality models
should be sufficient.
A registry may also have some, but not all, the information necessary to deter-
mine subtype. This could be the case when one or more of the tumor characteristics
that define the subtype have been recently recognized as important, and the registry
has yet to record information on those characteristics. Revisiting the example of four
breast cancer subtypes defined by the binary tumor characteristics ER and PR status,
the registry may have recorded ER status but not PR status. This registry would
provide marginal hazard rates by ER status, λm(ER+)(t) and λm(ER−)(t). In order
to obtain the subtype-specific marginal hazard rates λm(ER+,PR+)(t), λm(ER+,PR−)(t),
λm(ER−,PR+)(t), λm(ER−,PR−)(t), one could take the same approach but in this case
weighting the ER-defined marginal hazards by estimates of the finer subtype distri-
butions through a proportionality model fit with a supplemental data source. By
noting that λm(ER+,PR+)(t)+λm(ER+,PR−)(t) = λm(ER+)(t) and that λm(ER−,PR+)(t)+
λm(ER−,PR−)(t) = λm(ER−)(t), we see that is is only necessary to establish propor-
tionality models for two of the four subtypes, say λm(ER+,PR+)(t) and λm(ER−,PR+)(t),
as the remaining subtypes (in this case λm(ER+,PR−)(t) and λm(ER−,PR−)(t)) are then
defined.
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2.4 Summary and Absolute Risk Predictions
In this chapter we have discussed a number of different ways to estimate the key
components of a subtype-specific absolute risk model, depending on the characteristics
of the available data sources. Figure 1 summarizes which data sources can be used
to estimate each component, providing a road map for using different data sources
in conjunction with one another to develop the model. For instance, we could fit an
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absolute risk model by estimating the βj parameters and attributable risk (using the
distribution of covariates among cases) from a case-control study and combining those
estimates with subtype-specific marginal hazard rates from a registry and competing
mortality rates from a national survey. We also discussed ways to handle registry
data that is missing tumor subtype. Figure 2 adds these details to the overall picture
of which data can be used to estimate each model component.
The option to build absolute risk models by integrating multiple data sources
allows researchers to use the most appropriate choice available for each component
of the model, drawing on the strengths of different types of data. When multiple
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sources of data are available to fit a given model component, careful consideration
of characteristics such as the representativeness, sample size, sampling scheme, and
missingness of the data should go into deciding which source is ultimately the best
choice for estimating that component.
Typically once the subtype-specific absolute risk model is built, the goal is to use
the model to learn about the distribution of absolute risk for the subtypes of interest
in the population. This may mean looking at the proportion of the population that
exceeds clinically relevent thresholds of risk or evaluating risk differences associated
with a given risk factor for a particular subtype. Whatever the goal, in order to learn
about the distribution of risk in the population one must first use the fitted model
to predict risk for a set of covariate profiles that are representative of the population.
This representative set of covariate profiles could come directly from a cohort study or
from the controls in a population-based case-control study. The representative set of
covariate profiles could also be simulated from the joint distribution of the covariates
Z, perhaps estimated in a large national survey. In Chapter 4 we will demonstrate
these ideas by fitting a subtype-specific absolute risk model to real data, making risk
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predictions for breast cancer subtypes that are representative of the United States
population, and analyzing the resulting risk distributions to evaluate the impact of
risk factor modification on the distribution of risk for various subtypes. Before doing
so, we will first address the statistical challenge of variance estimation, characterizing
the uncertainty in risk predictions from an absolute risk model which is fit on multiple
sources of data.
2.5 Variance Estimation
Characterizing the uncertainty in subtype-specific absolute risk estimates is critical to
their use. An individual’s risk is estimated by applying the fitted absolute risk model
to the individual’s set of covariates. Thus, the variance of the risk estimate is directly
related to the variance of the parameters that comprise the fitted model. Variance
estimation in this context is challenging because we must account for the fact that
the risk estimate is a complex function of the various model parameters, which we
have shown may be estimated from multiple different sources of data. A given data
set may also be used to estimate more than one set of model parameters, in which
case a valid variance estimation procedure must account for covariance between the
estimates and how it ultimately affects the variance of the absolute risk estimate.
To construct a variance estimator that accounts for these features, we apply em-
pirical process theory, basing the variance calculation on influence functions. The
influence function approach has previously been applied to the problems of estimat-
ing the variance of attributable risk estimates from complex surveys and of estimat-
ing the variance of absolute risks for colorectal cancer (Graubard and Fears, 2005;
Freedman et al., 2009b). We extend the approach to the setting of subtype-specific
absolute risk models, handling influence functions for subtype-specific absolute risks,
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the reparametrized multinomial model for subtypes, and models of the subtype dis-
tribution.
For illustrative purposes, suppose the model is parametrized by β̂j, λ̂0jq for j =
1, ..., J and q = 1, ..., Qj for each subtype j. Generally, a risk estimate for subtype j
∗,
denoted Aj∗ , is simply a function of the parameter estimates Âj∗ = f(β̂j, λ̂0jq). Given
this general form, we express the risk estimate as a linear function of the parameter




















We then express each parameter estimate as a sum of independent identically dis-
tributed influence functions, which quantify the contribution of each data point to a
given parameter estimate, with β̂j − βj = 1N
N∑
i=1







































































By using influence functions, we express the risk estimate as an sum of independent
identically distributed contributions φi from each observation that was used to es-
timate the model parameters. Due to the central limit theorem, we know that the
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. With the proper formula for φ, we
can estimate this variance empirically by computing the variance of φi for all individ-
uals in the overall data. Again, this overall data may be comprised of observations
from multiple data sources.
Thus far we have described a general strategy for constructing a variance estimator
for risk estimates from a subtype-specific absolute risk model. However, the specific
formula for φ will depend on how the model is parametrized and how those parameters
are estimated. In this chapter we have provided many different options for modeling
and model fitting, which depend on the chosen data sources. In the following, we will
derive the formula of φ for one possible choice of model parametrization and fitting.
We present the mathematical details of variance calculation for the following





























(1− ARj(t)) ξj(t)λm+(u)eZβj + c(u)du
])
dt.
In Chapter 4 we fit this model to real data, so the variance calculation presented here
will reflect the characteristics of the data sources we use in the actual data analysis.
For instance, we obtain estimates of competing mortality c(t) from national survey
data and overall marginal hazard λm+(t) from a national cancer registry. These
data sources have large enough sample sizes that the estimates c(t) and λm+(t) are
essentially without variance, so in the variance calculation we treat these rates as
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known. Estimation of the subtype-specific attributable risks ARj(t), the subtype-
ratios ξj(t), and the log hazard ratios βj, all contribute variation to the variance of
the risk estimate Aj∗ .
The precise relationships depend on the model’s parametrization, which we for-
malize as
ARj(t) = ARjq when tq ≤ t ≤ tq+1 λm+(t) = λk when tk = t
ξj(t) = ξjp when tp ≤ t ≤ tp+1 c(t) = cl when tl = t.
We define the rates c(t) and λm+(t) by known parameters at integer ages tl for l =
1, ..., L and tk for k = 1, ..., K respectively. We define the functionsARj(t) and ξj(t) by
the subtype-specific scalar parameters ARjq and ξjp in sequential time intervals with
cutpoints tq and tp, allowing the functions to vary with time. Defining these functions
with more and finer intervals allows more flexible modeling with time, but requires
estimation of a greater number of parameters. The intervals should be selected to
jointly cover the time interval where risk prediction is desired with as much precision
as can be well-supported by the available data.
By expressing the model in terms of the parameters, we define the function










































As before, the first step in constructing a variance estimator for this model is to apply
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ψcjpi. We incorporate the






































































To obtain the formula for φi, we must compute the derivative of Aj∗ in terms of
each parameter and obtain the formula for the influence functions ψbji, ψajqi, and
ψcjpi. The derivatives are provided in Appendix F and the derivation of the influence
functions is given in Appendix G.
2.6 Simulations
To verify that the variance estimator given by equation (2.22) estimates the vari-
ance well, we evaluated its performance using simulations. We generated cohort
data by simulating two binary covariates, Z1 and Z2 with probabilities 0.2 and
0.5. We then simulated event times, T1 and T2, for two subtypes, S1 and S2,











respectively, which induce the specified log hazard ratios
β1 = [log(2), 0]
′ and β2 = [log(3), 0]
′. We selected parameters K1 = 3.22, L1 = 209.1,
K2 = 3.72, and L2 = 159.1 such that the hazard rates of simulated event times
approximately corresponded with breast cancer incidence rates in SEER. We also
simulated potential censoring times Tc from a normal distribution with mean 70 and
standard deviation 3.5. For each individual, the final event time T = min(T1, T2, Tc)
with the subtype S assigned accordingly, taking subtype 0 if censoring time occurred
first. Thus, the overall simulated data was comprised of variables [Z1, Z2, T, S].
For 1000 simulated datasets of size 800000, we fit the absolute risk model and
recorded absolute risk estimates for each of the two subtypes, and the corresponding
variance estimates, for individuals with two different covariate profiles: [Z1 = 0, Z2 = 0]
and [Z1 = 1, Z2 = 1]. Based on our knowledge of the true data generating distribu-
tions, we computed the true values of absolute risk for each subtype. Table 2.4
presents the average absolute risk estimates for ages 50-70 along with the percent
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bias on the scale of population risk per 1000 women.
Table 2.4: Average Estimates and Percent Bias of Absolute Risk in









Z1 = 0, Z2 = 0 19.92 19.91 -0.07
Z1 = 1, Z2 = 1 38.05 38.07 0.05
Subtype 2
Z1 = 0, Z2 = 0 34.37 34.39 0.08
Z1 = 1, Z2 = 1 98.32 98.51 0.19
The results show that our coded implementation of the model gives unbiased
estimate of the subtype-specific absolute risks, with estimates deviating from the
true values by less than one percent on average, in a non-systematic fashion. By
presenting the risk estimates applied to a population of size 1000, we see that in
a public health context the estimated number of predicted cancers would be off by
substantially less than one person on average.
In Table 2.5 we examined the performance of the robust variance estimator by
comparing the variance estimates to the “true” observed variation in risk estimates
over the 1000 datasets. Table 2.5 presents the estimated standard deviations of the
absolute risks in Table 2.4 as compared to the observed standard deviation, along with
coverage probability. The results show that the robust variance estimator performs
quite well, with coverage probability at the appropriate 95% level. These results
demonstrate that the influence function based approach is a valid way to obtain
variance estimates and is implemented correctly in our code.
Although the simulation results for the point estimates and robust variance esti-
mates of the absolute risk clearly show that the implemented method is working well,
to be thorough we also investigated the performance each estimated component in the
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Table 2.5: Average Standard Error Estimates and Coverage Probabilities of Absolute












Z1 = 0, Z2 = 0 0.223 0.219 0.944
Z1 = 1, Z2 = 1 0.587 0.586 0.954
Subtype 2
Z1 = 0, Z2 = 0 0.287 0.284 0.954
Z1 = 1, Z2 = 1 1.064 1.082 0.958
model: the log hazard ratios, the time-varying attributable risk, and the time-varying
subtype ratio. In the simulation, we model ARj(t) and ξj(t) by piecewise constant
functions defined by four categories of time: 30-49, 50-58, 59-65, and 66-85.
Table 2.6 presents the average estimates and percent bias for each of the model
components. The results show that across all model components the parameter es-
timates exhibit less than four percent bias on average, with less than one percent
bias in the majority of the estimates. Similarly, Table 2.7 presents the average robust
standard deviation estimates for each model component and the percent bias. Again,
the results show that the robust variance estimator is performing well, with under
five percent bias across all model components. Because the two subtype ratios for a
given time interval add to one, one estimate is fully determined by the other and we
expect them to have the same variance. This is the case in our simulation results.
Taken together, these simulation results empirically demonstrate the effectiveness
of the robust variance estimator we constructed from the influence functions for each
model parameter. This exercise also demonstrates that we implemented the method
correctly in R and can feel confident applying our code to address practical problems
using real data.
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Table 2.6: Average Estimates and Percent Bias of Model Components for Absolute
Risk Models for Two Subtypes, with Attributable Risk and Subtype Ratios Modeled











βz1 0.693 0.695 0.23
βz2 0 -2.744E-04 –
Subtype 2
βz1 1.099 1.100 0.13





t ∈ [30, 49] 0.165 0.165 -0.08
t ∈ [50, 58] 0.161 0.161 0.01
t ∈ [59, 65] 0.158 0.158 0.08
t ∈ [66, 85] 0.150 0.154 3.19
Subtype 2
t ∈ [30, 49] 0.283 0.282 -0.15
t ∈ [50, 58] 0.278 0.278 0.05
t ∈ [59, 65] 0.273 0.274 0.03





t ∈ [30, 49] 0.384 0.379 -1.33
t ∈ [50, 58] 0.348 0.348 0.15
t ∈ [59, 65] 0.334 0.333 -0.09
t ∈ [66, 85] 0.314 0.322 2.47
Subtype 2
t ∈ [30, 49] 0.616 0.621 0.83
t ∈ [50, 58] 0.652 0.652 -0.08
t ∈ [59, 65] 0.666 0.667 0.04
t ∈ [66, 85] 0.686 0.678 -1.13
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Table 2.7: Percent Bias of Robust Standard Deviation Estimates for Model Components
in Two Absolute Risk Models, with Attributable Risk and Subtype Ratios Modeled by













βz1 1.725E-02 1.708E-02 0.98
βz2 1.611E-02 1.584E-02 1.64
Subtype 2
βz1 1.348E-02 1.355E-02 -0.50





t ∈ [30, 49] 8.085E-03 8.033E-03 0.64
t ∈ [50, 58] 8.267E-03 8.081E-03 2.25
t ∈ [59, 65] 8.221E-03 8.221E-03 0.01
t ∈ [66, 85] 8.414E-03 8.345E-03 0.81
Subtype 2
t ∈ [30, 49] 6.189E-03 6.040E-03 2.41
t ∈ [50, 58] 5.915E-03 6.005E-03 -1.52
t ∈ [59, 65] 6.208E-03 6.214E-03 -0.11





t ∈ [30, 49] 3.681E-03 3.662E-03 0.51
t ∈ [50, 58] 3.755E-03 3.603E-03 4.04
t ∈ [59, 65] 3.531E-03 3.457E-03 2.10
t ∈ [66, 85] 3.223E-03 3.360E-03 -4.24
Subtype 2
t ∈ [30, 49] 3.681E-03 3.662E-03 0.51
t ∈ [50, 58] 3.755E-03 3.603E-03 4.04
t ∈ [59, 65] 3.531E-03 3.457E-03 2.10
t ∈ [66, 85] 3.223E-03 3.360E-03 -4.24
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2.7 Appendix A: Equivalence Between Two
Partial Likelihood Estimators
Beginning with the score function for the unconditional partial likelihood, we assign
non-parametric estimates for the hazard at time t and show that the resulting score
function is the same if we assume that there are no tied failure times. In doing so,
we show that in such a situation the unconditional partial likelihood estimator β̃j∗ is
equivalent to the conditional partial likelihood estimator β̂j∗
S(βj∗) =
























In Appendix B the non-parametric estimates defining the baseline hazard function at




































































If we assume that there are no tied failure times, then each dj(t(i)) is 0 or 1 based on
whether the single observed event at that time was of subtype j. This means that
J∑
j=1
dj(t(i)) = 1. Moreover, when the single event at a given time is not of subtype j
∗




























The only non-zero contribution in the denominator of the first term occurs when

































This is the score equation for the partial likelihood conditional on subtype.
2.8 Appendix B: Deriving the Subtype-Specific
Baseline Hazard Estimates
In the following equations, we derive the maximum likelihood estimator for param-
eters λjq which non-parametrically define the subtype-specific baseline hazard func-
tions λ0j. This likelihood formulation assumes that censoring is independent of the
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I {Si = j∗} I {tj∗q∗ = ti}
Q∑
q=1
































2.9 Appendix C: Deriving the Subtype-Specific
Baseline Hazard Estimates, Drawing Strength
Across Subtypes
Here we derive the non-parametric estimator of the referent baseline hazard function.




















We incorporate the new formulation of the proportional hazards model λj(t) =
λ01(t)hj(θj, t)e
βjzi based on a proportional relationship between the baseline hazard























Recall that we define the reference baseline hazard function λ01(t) non-parametrically
by parameters λ1, ..., λQ at each observed event time t1, ..., tQ, with zero hazard in
















































I {Si = j}λqI {tq = ti}
}










To obtain the profile likelihood estimate of a specific λq∗, we treat hj(θj, ti) and βj as






I {tq∗ = ti}∑
q=1

















































2.10 Appendix D: Estimating the Proportional-
ity Model Relating Subtype Baseline Hazard
Functions
To estimate the general function hj(θj, ti) for a particular subtype, we will obtain the
score function from the profile likelihood of θj. We begin with the likelihood from


























































































In general, estimation of θj∗ depends on the referent baseline hazard function λ01(ti)
and βj∗ . Thus, obtaining final estimates necessitates iteratively solving the estimating
equations for all the parameters.
In the case of the simple proportionality model where hj(θj, ti) = θj, and corre-






























where dj∗ is the number of observed events of subtype j
∗ irrespective of the time that
those events occurred. This is not particularly surprising due to the fact that the
model hj(θj, ti) = θj is not time-varying.
2.11 Appendix E: Influence Function for x̄ȳ
Suppose xi and yi are independent and identically distributed where x ∼ F0, µx =
E[x] and y ∼ G0, µy = E[y]. Our goal is to derive the influence function ψi associated
with the estimator x̄
ȳ
. To do this, we first express the estimator x̄
ȳ
as a function of the
empirical distributions Fn and Gn, and the parameter
µx
µy
as a function of the true

































can be expressed as the derivative of the function φ that maps
the distribution functions to the estimate and parameter. The empirical distributions
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as a sum of indpendent identically distributed in-







. We take this derivative in the direction
of the true distributions by taking the derivative of φ along a “line” in the space of
distributions, defined as a convex combination of the empirical and true distributions













(1−t) F0+t δxi (x)







x d {(1− t) F0 + t δxi(x)}∫
















We simplify this expression by recognizing the relationships
∫
x d {F0} = µx
∫
y d {G0} = µy
∫
x d {δxi(x)} = xi
∫
y d {δyi(y)} = yi.
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We then take the derivative with respect to t and evaluate at t = 0 to obtain the
























2.12 Appendix F: Derivatives for the Variance
Calculation









through a combination of straight-
forward calculus and careful bookkeeping. For ease of calculation, we work with an




















































exp (h (βj, ARjq, ξjp)). Thus, the derivatives needed for the















































































2.13 Appendix G: Influence Functions for the
Variance Calculation
The final elements needed for the variance calculation are the influence functions,


























ψcjpi. The form of these influence functions depends on how
the parameters are estimated.
When we ultimately fit the model in Chapter 4, we estimate the Cox parameters
βj using the multinomial likelihood method applied to cohort data. In Section 2.2.3
we derived the efficient influence function associated with the multinomial maximum
likelihood estimator, accounting for the presence of nuisance parameters. With ex-
pectations replaced by empirical means, those formulas can be used to compute ψbji
for each observation in the cohort data used to estimate βj. For all observations that
were in some way used in model fitting, but that did not contribute to estimation of
the β̂j’s, the influences ψbji = 0.
The influence function ψcjpi should reflect the independent and identically dis-









the empirical estimate of the proportion tumors in time interval [tp, tp+1] that are
subtype j. In Appendix E, we derive the influence function for estimators of this
general form: x̄
ȳ






















In the actual variance estimate, we approximate the expectations with empirical
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As before, for all observations that contributed to model fitting but were not used
to estimate ξ̂jp, the influences ψcjpi = 0.
Finally, we derive the influence function ψajqi associated with ÂRjq. In Chapter
4, we estimate ÂRjq in time strata defined by [tq, tq+1] using the Bruzzi formula




























The variance of ÂRjq depends on the variance of β̂j, P̂jq, and the empirical variance in
the distribution of the indicators. To take all these sources of variation into account
in the influence function of ÂRjq, we again use a Taylor’s approximation and influence
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Let F0 denote the joint distribution of S, T, and Z


















































The influence function ψbji for β̂j should be obtained as previously discussed. Deriving
the influence function for P̂jq is straightforward in that the estimator is linear, needing





The last component needed for the influence function of ÂRjq is the influence





ψeji. We solve for ψeji
using the same approach as employed in Appendix E, expressing ÂRjq and ARjq as a
function φ of the empirical distribution Fn and the true distribution F0 respectively,
and taking the derivative in the direction of the true distribution through a scalar
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(δSi,Ti,Zi(S, T, Z)− F0) =
d
dt














































Putting these components together, and replacing true values with estimates and











ψpjqi + ψeji + op(1).
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Chapter 3
Building Calibrated Risk Models
by Leveraging Information from
Published Models
This chapter contains material in preparation to be published in collaboration with
Raymond Carroll and Nilanjan Chatterjee.
3.1 Introduction
In the previous chapter, we presented methodology for building an absolute risk
model from scratch by integrating information from multiple data sources. However,
in many cases a published risk model based on known risk factors may already exist
in the literature. If that is the case, the main reason for building a new absolute risk
model would be to update the model to include newly identified risk factors, such as
lifestyle factors or biomarkers, along with the existing ones.
In this chapter, we investigate methodology for updating risk models with new
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risk factor information while incorporating information from existing models as much
as possible. Specifically, we consider a regression calibration estimator that has tra-
ditionally been used to increase the efficiency of estimation by calibrating to external
data that comes from the same underlying population as the sample data. We seek
to understand whether this estimator is also useful for calibration in contexts where
the two populations are not the same.
The main question we address is whether the regression calibration estimator pro-
duces meaningful results when the sample and the external data are representative
of different populations, and under what conditions. First, we describe the statis-
tical formulation of the problem along with a few motivating examples and set up
basic notations. We then review the regression calibration approach and go on to
show analytically that applying the regression calibration estimator when the two
populations are different produces an estimate of the external population parameters
under certain conditions. In particular, we identify a key mapping that implicitly
relates parameters of interest through the population distribution. We show that if
this mapping is common for the two populations, then the regression estimator is
unbiased for the external population parameters up to a Taylor’s approximation. In
addition, we provide a variance estimator that is appropriate for this setting. We
also conduct extensive simulations to assess the estimator’s bias and variance in a
variety of settings, numerically corroborating our analytic results. Finally, we discuss




Let Y be an outcome of interest and X be a set of covariates upon which a published
model for the predictive distribution g(y|x) has been built. In general, we will assume
that we have only access to the model, but not necessarily to the individual level data
from the “external study” upon which the original model was built. Let Z be a set of
new covariates based on which the model needs to be updated. We assume that data
on Y , X and Z are available to us from an “internal study” for building such a model.
We are interested in the case where our internal study sample, which is representative
of some underlying population P I , may differ in some respects from the underlying
population that we want to model, PE, due to characteristics of the study design or
sampled population. We envision a situation where the external, published study is
representative of the population of interest, PE, and can thus help produce results
that are more generalizable to that population. To make this less abstract, we present
two specific examples.
Example 1.
It is often of interest to develop a logistic model for disease risk prediction of the
form: logit P(D = 1|Z,X) = β0 + βXX + βZZ + βXZXZ, where X are established
environmental and lifestyle related risk factors and Z is a set of new biomarkers, such
as genetic susceptibility markers.
In a logistic model, the intercept parameter β0 captures information related to
the disease rate in the population. It is well known that under case-control sam-
pling the estimated intercept parameter is not unbiased for β0, but instead for β
∗
0 =
β0+log(π1/π0), where π1 and π0 denote the sampling probability for cases and controls
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from the underlying population. To make adequate risk predictions, the estimated
intercept parameter must be representative of the disease rate in the underlying pop-
ulation. To obtain a corrected estimate that reflects the true underlying β0, one can
benefit by leveraging external information in the estimation of β̂0.
Initial biomarker data are often collected in case-control studies, where differential
participation of cases and controls by factors related to lifestyle or behavioral factors
can lead to selection bias in the associated risk parameter estimates, βX . However,
if the selection of participants does not depend on the biomarker Z conditional on
lifestyle factors X, one can still obtain unbiased estimates for the risk parameters βZ
and βXZ from a case-control study. If that is the case, it may be desirable to estimate
the parameters βZ and βXZ from the case-control study, but utilize information from
external models to assist in estimation of βX , which is susceptible to selection bias in
the internal case-control data.
Example 2.
For late-onset chronic diseases, risk models typically require specification of an age-
window over which prediction is desired. In this setting it is natural to consider
models that incorporate time-to-event as an outcome. To that end, it is common
to develop Cox proportional hazard models of the form λ(t|X) = λ0(t) exp(βTX),
where λ(·|X) denotes the instantaneous hazard function given risk factor information
X, λ0(t) denotes the baseline hazard function and β denotes the vector of hazard-
ratio parameters. As we described in Section 2.2, hazard ratio parameters β can be
estimated from cohort studies, case-cohort studies or even case-control studies that
use appropriate incident density sampling design by applying Cox partial-likelihood or
conditional logistic regression methods. These hazard ratios β are generally thought
to be transportable across populations even though the distributions of risk factors
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may differ.
Estimates of λ0(t) can obtained from such studies using Breslow’s method or
variations of it that can take into accounting the sampling of cases and controls within
a cohort. However, if the internal study data is not representative of the population of
interest then the resulting baseline hazard rates λ0(t) will also not be representative.
For example, Nurses Health Study is a widely used cohort study that has been used
for etiologic investigation of many disease outcomes (Colditz et al., 1997). Although
this study has proven to be a tremendous resource for understanding relative risks
associated with various etiologic causes of various outcomes, any estimate of baseline
risks λ0(t) from this cohort would probably not be representative of the general US
population because the cohort of participating nurses is likely healthier. If the goal
is to build a risk model for the US population using the Nurses Health Study cohort,
one would benefit from incorporating external “models” (perhaps just simple marginal
disease rates) when estimating λ0(t) part of the model.
We have talked about the fact that national disease registries, such as the SEER
registry for cancer, are excellent sources of external data for building risk models in
this context. Registry data can be used to obtain estimates of nationally representa-
tive age-specific hazard rates for many diseases. Gail et al. (1989) pioneered a method
for utilizing this type of external data to estimate the baseline hazard λ0(t) such that
the corresponding marginal hazard function (i.e. the hazard function averaged over
the covariate distribution) is calibrated to population hazard estimates provided by
the registry. In Chapter 2 we extended those ideas to the setting of subtype-specific
risk models. In fact, both of these approaches, which build absolute risk models
that are in some sense “calibrated” to registry data, are special cases of the general
problem we have described.
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Statistical Framework
Our goal is to develop a parametric model of the form fβEx ,βEz ,βEzx(Y |X,Z) for the
population of interest PE. We explore doing this by using a sample of population
P I and calibrating to external information on PE. βEx denotes a set of parameters
associated with the original risk factors X, βEz denotes the main effect parameters
associated with new risk factors Z, and βExz denotes the possible interactions of Z
with the existing risk factors X. A model of the same form for population P I is
parametrized by βIx, β
I
z , and β
I












xz], so that βz, βxz are transportable between the populations. This
assumption is needed in order to build the model as the external study provides no
information on the new covariates Z.
3.2.1 Background: Links with Survey Methodology
Thus far we have spoken generally of calibrating to the information in existing models
and external datasets when developing an updated risk model. The problem of how
to perform such a calibration has strong links to a well-developed statistical area,
namely survey methodology, that we can draw upon. There is a wide literature
about how to use external data sources to improve inference for parameter estimates
from sample surveys. For a simple introduction to the methodology, consider the
problem of estimating the population mean µW from a survey that collects random
variables W and auxiliary variables V when the population mean µV is available from
a census. In this setting, commonly used calibration estimators take the form
µ̂CalW = W + c× (µV − V ), (3.1)
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where W and V are sample means for W and V , possibly taking into account sample-
weights if non-random sampling is used, and c is a constant factor. Since (V − µV )
is an unbiased estimator for 0 and W is unbiased for µW , for any constant c, µ̂
Cal
W
is an unbiased estimator of the desired quantity, µW . The optimal estimator, which
minimizes the variance in this class, is given by choosing copt = cov(V ,W )/var(V ).
Calibration estimators increase the efficiency of parameter estimation for µW by lever-
aging information on the relationship between W and V in the data and knowledge
of µV .
The same basic idea can be applied to the problem of calibrating a new model to an
existing one. In the model framework described previously, suppose the reduced model
g(y|x) is specified in terms of a set of parameters θ. Let θ̂E and θ̂I denote the max-
imum likelihood estimates from fitting a reduced model to the external and internal
study respectively; analogously, let β̂I denote the maximum likelihood estimate from
fitting the full model fβ(y|x, z) to the internal study. Denote the corresponding score
functions as U(Y |X; θ) = ∂ log g(y|x; θ)/∂θ and S(Y |X,Z; β) = ∂ log f(y|x, z; β)/∂β
for the reduced and full models respectively.
Analogously to the estimator defined in (3.1), a calibration estimator can be de-




















U(Y |X; θ)UT (Y |X; θ)
]
, C12 = ESI
[
S(Y |X,Z; β)UT (Y |X; θ)
]
,
and ESI denotes the sample expectation based on the internal study. It is easy to see
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that the maximum likelihood estimators β̂I and θ̂I can be asymptotically represented
as sample means of the form
β̂I = D−11 ESIS(Y |X,Z; β), and θ̂I = D−12 ESIU(Y |X; θ).
Thus, the estimator proposed by Chen and Chen is essentially same as the regression
calibration estimator of the form (3.1), but substituting W = D−11 S(Y |X,Z; β) and
V = D−12 U(Y |X; θ). When the internal and external populations are identical, it is
evident that the estimator (3.1) is asymptotically unbiased because β̂I is a consistent
estimator of βE = βI and (θ̂E− θ̂I) is a consistent estimator of zero. However, we are
interested in the more general problem of calibration when the internal and external
populations may differ in some respects, and it is not clear what the asymptotic limit
of βcal is when the underlying populations are different.
3.3 Characterizing Bias for the Calibration
Estimator
In the following, we show that under certain conditions the asymptotic limit for the
calibration estimator provides a first-order Taylor’s approximation for βE.
We assume that f(Y |X,Z, β) specifies a correct model for the conditional distri-
bution P(Y |X,Z) for both the internal and external study populations, which have
parameters βI and βE respectively; we will refer to this assumption as (A1). We also
assume that c22 = EPI
[
U(Y |X; θ)UT (Y |X; θ)
]
is invertible, where EPI denotes the
population expectation based on the internal study; this is assumption (A2).
Let q(β) = θ define a mapping between the limiting values of the maximum-
likelihood estimates θ̂ and β̂. In Appendix A, we show that such a mapping can be
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implicitly defined by the equation
∫
Y,X,Z
U(Y |X; θ) f(Y |Z,X; β) P (Z|X) P (X) dY dXdZ = 0. (3.3)
The mapping can be common for the internal and external populations, even when
the underlying limiting parameter values are not necessarily the same for the two
populations, i.e., q(βI) = θI and q(βE) = θE but possibly β
I 6= βE or θI 6= θE. This
mapping plays a key role in understanding whether the calibration estimator will
estimate meaningful parameters in a given context.
Proposition. Assume (A1), (A2). If the mapping θ = q(β) defined by equation
(3.3) is the same between populations PE and P I , then the calibration estimator β̂cal,
as defined in equation (3.11), provides an unbiased estimator for βE, the parameters
of the external population, up to a one-step Taylor’s approximation.
Sketch of the Proof. Beginning with equation (3.11) and incorporating the
mapping given by equation (3.3), we can write the asymptotic limit of β̂cal as
βcal = β







where d1, d2, c12, c22 are defined the same way as D1, D2, C12 and C22 respectively,
but replacing the sample expectation ESI by the population expectation EPI .
In order to understand βcal better, we establish some useful relationships. First,































Incorporating the relationships (3.5), (3.6), and (3.7) sequentially into (3.4), we show
that the asymptotic limit of β̂cal is
βcal = β






















































Thus, β̂cal provides a first-order Taylor’s approximation for β
E.









; however, by the mean value theorem we know









for some β∗ ∈ [βE, βI ]. When the form of q(β) is linear, the derivative ∂q(β)∂βT is a
constant and thus the relationship in (3.8) is exact. Correspondingly, the closer
q(β) is to being linear, the better the approximation. However, in situations where
q(β) is non-linear and βE 6= βI , the relationship will always be approximate, even
asymptotically. In Section 3.5 we examine the performance of this approximation in
83
a number of realistic scenarios by way of numerical simulation.
Conditions for the Implicit Mapping to be Common
To determine when the mapping is common for the internal and external popula-
tions, we examine each element of (3.3) that defines the implicit mapping. The
forms of the reduced model and the full model are the same for the internal and
external populations, so the U(Y |X; θ) and f(Y |Z,X; β) parts of the mapping are
always common. Thus, for the entire mapping to be common, in general one needs
P I(Z|X) = PE(Z|X) and P I(X) = PE(X), which is to say that the joint distribution
of X and Z must be the same for the two populations.
In Appendix D we consider the special case where the reduced model g(Y |X, θ)
is also correctly specified, such as when the model is saturated, and show that the
mapping can be implicitly defined by
∫
Y,Z
U(Y |X; θ) f(Y |Z,X; β) P (Z|X) dY dZ = 0 for each value of X.
This mapping does not depend on P (X), so if the reduced model is correctly specified
it need only be the case that P I(Z|X) = PE(Z|X) for the mapping to be common for
the two populations. This underscores that P I(Z|X) = PE(Z|X) is the more critical
assumption, a finding which we later confirm by simulation.
It is worth noting that at no point, in either the special or the general case, was it












or between θI and θE for the mapping to be common. It is rather remarkable that
these risk parameters and disease rates for the internal and external populations could
be quite different and yet the calibration estimator still provides a good approximation
of the full model risk parameters for the external population.
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3.4 Variance Estimation
Deriving the variance estimator in this context is fairly straightforward. To simplify
notation, we express the estimator as
β̂cal = β̂
I +M(θ̂E − θ̂I) where M = D−11 C12C−122 D2.
The elements of M are Fisher’s information matrices and converge more quickly than
the maximum likelihood estimators, so here we treat them as constant matrices.













+ 2 · Cov
[
β̂I , M(θ̂E − θ̂I)
]
.
The internal estimates β̂I , θ̂I and the external estimates θ̂E are estimated on different
























Letting ΣE denote the robust variance estimator for the existing model θ̂
E, and













MT − 2 · (D−11 C12D−12 )MT .






























This variance expression takes into account the variance in the external model, de-
noted ΣE, as well as the covariance between the reduced and full internal models.
In the next section we examine the performance of this variance estimator in sim-
ulations and show that it results in confidence intervals with appropriate coverage
probabilities.
3.5 Simulations
To evaluate the performance of the calibration estimator, we considered a simple
simulation setting with an existing risk factor X and a new risk factor Z, related to
a binary outcome Y through a full logistic model parametrized by β, P (Y |X,Z) =
expit(β0 + βxX + βzZ + βxzXZ).
3.5.1 The Binary Covariate Setting
We first consider a setting with binary X and Z, defining the the joint distribution
(Y,X,Z) through the parameters Px = P (X = 1), Pz0 = (Z = 1|X = 0), Pz1 =
P (Z = 1|X = 1), and β = [β0, βx, βz, βxz]T . We defined the true underlying popula-
















Similarly, the underlying distribution represented by the available sample P I was






We examined many settings where P I differed from PE with respect to one or
more of these various features of the population distribution. We classify the different
settings into Scenarios 1 through 4, with simulation parameters given in Table 3.1. In
Scenario 1, the populations P I and PE are identical. In Scenario 2, all features of the





]T 6= [βE0 , βEx ]T .
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Table 3.1: Simulation Parameters for the Binary Covariate Setting,
Defining Scenarios in which the Internal and External Populations Differ with Respect
to Various Features of the Population Distribution
Parameters
Px Pz0 Pz1 β0 e
βx eβz eβxz
External Population True Values 0.5 0.7 0.3 -3 0.85 2 1.2
Internal
Population
Scenario 1 - - - - - - -
Scenario 2 - - - -2.5 0.6 - -
Scenario 3
0.2 - - -2.5 0.6 - -
0.35 - - -2.5 0.6 - -
0.5 - - -2.5 0.6 - -
0.65 - - -2.5 0.6 - -
0.8 - - -2.5 0.6 - -
Scenario 4
0.8 0.85 0.15 -2.5 0.6 - -
0.8 0.7 0.3 -2.5 0.6 - -
0.8 0.55 0.45 -2.5 0.6 - -
0.8 0.4 0.6 -2.5 0.6 - -
0.8 0.25 0.75 -2.5 0.6 - -
“-” indicates that the internal and external population parameters are the same
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]T 6= [βE0 , βEx ]T and P Ix 6= PEx . Finally, in Scenario 4 all sim-
ulation parameters differ between P I and PE, including the conditional distributions
P I(Z|X) and PE(Z|X). In all simulation settings, we let the parameters associated












For each simulation setting, we conducted 5000 simulations where we generated
a cohort of size 150,000 from PE and obtained an estimate of θ̂E for the reduced
model P (Y |X) = expit(θ0 + θxX), representing the existing model toward which to
calibrate. We then generated a case-control sample with 1000 cases and 1000 controls
from P I , according to the parameters of the given simulation setting. We fit the full
model P (Y |X,Z) = expit(β0 + βxX + βzZ + βxzXZ) from the sample of P I using
both standard logistic regression and the calibration estimator, calibrated to θ̂E. In
the binary covariate setting we have defined, both the full and reduced models are
saturated and hence correctly specified. Thus, the conditions for a common mapping
are satisfied in all scenarios except Scenario 4.
Investigating Bias in the Binary Covariate Setting
In Table 3.2, we present the bias and mean squared error for β̂0 and β̂x, with respect to
the true parameters in the population of interest, βE0 and β
E
x , for both the calibration
estimator and the standard logistic regression estimator. In these simulations,
estimation of β̂z and β̂
I
xz is not impacted by calibration, so the basic logistic regression
estimates and the calibration estimates are identical and unbiased (not presented).
Across all simulation settings, the standard logistic regression estimator is biased for
the intercept βE0 . This is to be expected, as it is well known that logistic regression
with case-control sampling yields a biased estimate of the intercept parameter. The
calibration estimator is based on a case-control sample as well, but by calibrating to
88
Table 3.2: Percent Bias (Mean Squared Error) of the Calibration Estimator and the
Standard Logistic Regression Estimator for Estimating Log Odds Ratios in the
External Population, βE, in the Binary Covariate Setting for Simulation Parameters




cal basic cal basic
Scenario 1 0 (0.01) -88 (6.96) -1 (0.02) 0 (0.02)
Scenario 2 0 (0.01) -92 (7.71) 0 (0.02) 214 (0.14)
Scenario 3
0 (0.01) -86 (6.71) 5 (0.02) 219 (0.16)
0 (0.01) -89 (7.19) 1 (0.02) 213 (0.15)
0 (0.01) -92 (7.71) -1 (0.02) 212 (0.14)
0 (0.02) -96 (8.33) 1 (0.02) 216 (0.15)
0 (0.03) -100 (9.03) 2 (0.03) 216 (0.16)
Scenario 4
3 (0.07) -102 (9.50) -151 (0.12) 214 (0.19)
0 (0.03) -100 (9.00) -3 (0.03) 212 (0.16)
-3 (0.02) -98 (8.62) 145 (0.07) 217 (0.15)
-7 (0.05) -95 (8.20) 284 (0.23) 215 (0.15)
-10 (0.10) -93 (7.84) 421 (0.49) 215 (0.15)
“cal” refers to the calibration estimator
“basic” refers to the standard logistic regression estimator
89
the existing study, the method corrects the intercept estimate to be consistent with
the external population. As we expect, in Table 3.2 we see that the calibration of the
intercept parameter provides unbiased estimates of βE0 in all settings except Scenario
4, where we know the common mapping assumption is violated. In Scenario 1 we see
that both estimators are unbiased for βEx , which is also expected.
In Scenario 2 we see that when the risk parameters differ, the basic logistic estimate
is heavily biased for βEx . This is the case because it is unbiased for β
I
x 6= βEx . The
calibration estimator exhibits no bias for either parameter, supporting our analytic
finding that the risk parameters do not need to be the same for two populations in
order for calibration to be effective.
In Scenario 3, we see that the calibration estimator is unbiased for βE0 and ap-





risk parameters differ as well. This is consistent with our analytic finding that when
the reduced model is correctly specified, we need not assume that Px is the same for
the common mapping assumption to hold. The calibration estimator does exhibit a
small degree of bias for βEx . This is consistent with our analytic observation that even
asymptotically the calibration correction will still be approximate. However, under
the specified difference in the risk parameters, we see that this approximation is very
good. The standard logistic regression estimator is biased for both parameters for
the same reasons as in Scenarios 1 & 2.
In Scenario 4, we know that the assumption of a common mapping does not hold,
so we do not expect the calibration estimator to be unbiased. Indeed, we see that as
the magnitudes of deviation between P I(Z|X) and PE(Z|X) increase, the calibration
estimate of βEx becomes seriously biased. However, it is worth noting that the degree
of bias in estimation of the intercept parameter is relatively small, even when the
P (Z|X) distributions are significantly different.
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Confidence Interval Coverage in the Binary Covariate Setting
In Table 3.3 we present the percent bias and coverage probability for the estimates of
standard deviation associated with the calibration estimates and the standard logis-
tic regression estimates. The estimates of the standard deviation for the calibration
Table 3.3: Percent Bias (Coverage Probability) for the Estimated Standard Errors
of the Calibration Estimator and the Standard Logistic Regression Estimator for the
Log Odds Ratios in the External Population, βE, in the Binary Covariate Setting for




cal basic cal basic
Scenario 1 0 (0.95) 7 (0.00) 1 (0.95) 0 (0.95)
Scenario 2 0 (0.95) 8 (0.00) 0 (0.95) 1 (0.37)
Scenario 3
-1 (0.95) 11 (0.00) 1 (0.95) 0 (0.51)
0 (0.95) 10 (0.00) -1 (0.95) 0 (0.39)
-1 (0.95) 7 (0.00) -1 (0.95) -1 (0.38)
-2 (0.95) 4 (0.00) -2 (0.95) -1 (0.42)
0 (0.95) 3 (0.00) 1 (0.95) 0 (0.56)
Scenario 4
0 (0.94) 1 (0.00) 0 (0.83) -1 (0.74)
-1 (0.95) 2 (0.00) -1 (0.95) -1 (0.58)
0 (0.86) 4 (0.00) 0 (0.58) 0 (0.45)
2 (0.41) 7 (0.00) 1 (0.04) 1 (0.43)
0 (0.01) 7 (0.00) 0 (0.00) 0 (0.47)
“cal” refers to the calibration estimator
“basic” refers to the standard logistic regression estimator
estimator are given by the variance calculation derived in Section 3.4. These results
show that in settings where the calibration point estimates are unbiased, namely Sce-
narios 1 through 3, the estimates of standard deviation for the calibration estimator
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are unbiased as well, with coverage probabilities right at the appropriate 0.95 level.
In Scenario 4 where the calibration estimator showed substantial bias, the coverage
probabilities are understandably poor. Similarly, in the scenarios where the standard
logistic regression point estimates were biased, which include all except the Scenario 1
estimate of βEx , the coverage probabilities for the standard logistic regression estimates
are unacceptably low.
3.5.2 The Continuous Covariate Setting
Having thoroughly explored the setting of binary covariates, we now turn our at-
tention to the context of continuous covariates. Specifically, we consider the case
where X and Z are multivariate normal. To be consistent with our setup for bi-
nary covariates, we define the joint distribution P (Y,X,Z) by P (X) ∼ N (µx, σx),




, and β as before. In all settings, we set the parameters of
the marginal distribution of Z to be µz = 0 and σz = 0.4. Given these parameters,
it is well known that the parameters of the conditional distribution Z given X are










xz is the co-
variance between X and Z (Seber and Lee, 2003). After computing the parameters for
the conditional distribution of Z given X, we choose to either shift the mean µz|x by
δz|x or scale the standard deviation σz|x by γz|x. With this setup, the joint distribution
P (Y,X,Z) is fully specified by the simulation parameters µx, σx, σ
2
xz, δz|x, γz|x, and
β.
We investigate the performance of the calibration estimator in situations where
these features may differ between the true underlying population, PE, and the popu-
lation represented by the sample, P I . Again, we organize the simulations into Scenar-
ios 1 through 4 that correspond with those for the binary covariate simulations, and
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present the simulation parameters in Table 3.4. In simulating PE we did not manip-
ulate the distribution of P (Z|X) at all, i.e. δz|x = 0 and γz|x = 1. In Scenario 1 the
Table 3.4: Simulation Parameters for Continuous the Covariate Setting,
Defining Scenarios in which the Internal and External Populations Differ with Respect




xz δz|x γz|x β0 e
βx eβz eβxz
External Population True Values 0.0 0.5 0.1 0 1 -3 0.85 2 1.2
Internal
Population
Scenario 1 - - - - - - - - -
Scenario 2 - - - - - -2.5 0.6 - -
Scenario 3
0.15 - - - - -2.5 0.6 - -
0.30 - - - - -2.5 0.6 - -
0.45 - - - - -2.5 0.6 - -
- 0.3 - - - -2.5 0.6 - -
- 0.8 - - - -2.5 0.6 - -
Scenario 4
0.3 - - 0.15 - -2.5 0.6 - -
0.3 - - 0.3 - -2.5 0.6 - -
0.3 - - - 0.7 -2.5 0.6 - -
0.3 - - - 1.3 -2.5 0.6 - -
0.3 - 0 - - -2.5 0.6 - -
0.3 - 0.19 - - -2.5 0.6 - -
“-” indicates that the internal and external population parameters are the same
underlying populations PE and P I are the same. In Scenario 2 the risk parameters
for P I differ from PE. In Scenario 3 the distribution P I(X) differs from PE(X),
first by shifting the mean µx and then by altering the standard deviation. In all
settings in Scenario 3, the risk parameters for the two populations differ as well. In
Scenario 4 the distribution P I (Z|X) differs from PE (Z|X), first by shifting the con-
ditional mean by δz|x, then by scaling the conditional standard deviation by γz|x, and
lastly by changing the covariance of X and Z through parameter σ2xz. In addition, in
Scenario 4 the risk parameters and the distribution of P (X) differ as well.
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Again, in each simulation scenario we performed 5000 simulations, generating a
cohort study of size 150,000 from PE and a case-control study with 1000 cases and
1000 controls from P I , fitting models of the same form as in the binary case. However,
with continuous covariates it is no longer the case that the existing reduced model
is correctly specified; thus, the common mapping assumption will not satisfied in
cases where either P (X) or P (Z|X) differ between the populations (Scenarios 3 and
4). Accordingly, we do not expect the calibration estimator to be unbiased in those
settings.
Investigating Bias in the Continuous Covariate Setting
In Table 3.5, we present the bias and mean squared error for the calibration estimator
and the standard logistic regresssion estimator with respect to the true parameters
in the population of interest PE for the simulation settings described. In these sim-
ulations, the calibration estimate of β̂z is not impacted by calibration and thus the
results are identical to those for the standard logistic regression estimator and unbi-
ased in all settings; however, calibration estimate of β̂xz is affected by calibration in
these settings and will be discussed. As before, the basic logistic regression estimator
is significantly biased for the intercept parameter due to case-control sampling.
The results in Scenarios 1 and 2 mirror what we observed for binary covariates.
In Scenario 1 where the underlying populations are the same, both methods provide
unbiased estimation of all parameters, except for the standard logistic regression
estimator which is biased for the intercept as previously discussed. Scenario 2 shows
that when the risk parameters differ, the calibration method is unbiased for the
intercept. However, the calibration estimator of βEx shows some bias due to the
fact that the calibration is approximate, even asymptotically. We also see that the
magnitude of bias in the continuous covariate setting is greater than the bias observed
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Table 3.5: Percent Bias (Mean Squared Error) of the Calibration Estimator and the Standard
Logistic Regression Estimator for Estimating Log Odds Ratios in the External Population, βE,








cal basic cal basic cal basic cal basic
Scenario 1 0 (0.00) -98 (8.72) 2 (0.00) -1 (0.01) 0 (0.02) 0 (0.02) 2 (0.04) 1 (0.04)
Scenario 2 0 (0.00) -98 (8.71) -12 (0.00) 215 (0.13) 0 (0.02) 0 (0.02) -1 (0.05) -1 (0.04)
Scenario 3
-1 (0.00) -101 (9.16) -4 (0.00) 215 (0.13) 0 (0.02) 0 (0.02) 1 (0.05) 2 (0.04)
-3 (0.01) -103 (9.62) 4 (0.00) 216 (0.13) 0 (0.02) 0 (0.02) 2 (0.04) 2 (0.04)
-5 (0.02) -106 (10.09) 12 (0.00) 215 (0.13) 0 (0.03) 0 (0.03) 2 (0.05) 1 (0.04)
-1 (0.00) -99 (8.81) 307 (0.30) 211 (0.19) 0 (0.04) 0 (0.04) 0 (0.09) 1 (0.08)
0 (0.00) -97 (8.47) -121 (0.04) 216 (0.13) 0 (0.02) 0 (0.01) 2 (0.03) 0 (0.02)
Scenario 4
1 (0.00) -100 (8.94) 23 (0.01) 217 (0.14) 0 (0.02) 0 (0.02) 3 (0.04) 3 (0.04)
4 (0.02) -96 (8.29) 39 (0.01) 215 (0.14) 0 (0.02) 0 (0.02) 2 (0.04) 2 (0.04)
-3 (0.01) -104 (9.71) 0 (0.01) 216 (0.14) 1 (0.04) 1 (0.04) 1 (0.06) 1 (0.06)
-2 (0.01) -103 (9.49) 10 (0.00) 214 (0.13) 0 (0.01) 0 (0.01) 4 (0.03) 4 (0.03)
0 (0.00) -103 (9.54) -169 (0.08) 215 (0.13) 0 (0.02) 0 (0.02) -1 (0.07) 1 (0.05)
-6 (0.04) -104 (9.71) 177 (0.16) 217 (0.21) 1 (0.14) 1 (0.13) 0 (0.03) 0 (0.03)
“cal” refers to the calibration estimator
“basic” refers to the standard logistic regression estimator
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in the binary covariate case. The standard logistic regression estimate is unbiased for
βIx 6= βEx , so we observe significant bias with respect to βEx .
In Scenario 3, we see that when the mean of the distribution P I(X) is shifted
relative to PE(X), the calibration estimates of β0 and βx are biased. The bias in the
intercept β0 is negligible, while the bias for βx is more substantial, increasing in mag-
nitude as the size of the shift in mean increases. Changing the distribution of P (X)
through the standard deviation, such that σIx 6= σEx , does not bias the calibration
estimate of the intercept parameter but results in substantial bias in the calibration
estimate of βx. It appears that differences in the mean affect the calibration estimate
of the intercept more than differences in the standard deviation of P (X), whereas the
opposite is true for estimation of β̂x. The calibration estimator shows a small degree
of bias for βxz. Standard logistic regression is unaffected by the distribution of the
covariates, and accordingly its performance is the same as in Scenario 2 in all cases,
with the observed bias attributable to differences in the risk parameters.
In the first two settings of Scenario 4, we observe that differences in the mean of
the conditional distribution P (Z|X) result in a small degree of bias in the calibration
estimate of β0 and somewhat greater bias in the calibration estimate of βx, with bias
increasing as the difference in means, δz|x, increases. However, in the next two settings,
we observe that differences in the standard deviations of P (Z|X) do not result in
bias for the calibration estimate of β0 and only negligible bias for the calibration
estimate of βx. Differences in the covariance of X and Z do not particularly impact
the calibration estimator of β0, but do substantially affect estimation of βx. The
calibration estimates of βxz show a small degree of bias when the conditional means
differ. As we noted previously, the performance of standard logistic regression does
not depend on the distribution of the covariates, so again it performs similarly as in
Scenario 2.
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Confidence Interval Coverage in the Continuous Covariate Setting
In Table 3.6 we present the percent bias and coverage probabilities for the standard
deviation estimates that arise from the variance calculation derived in Section 3.4 in
the continuous covariate simulation scenarios. In general, the true standard deviations
Table 3.6: Percent Bias (Coverage Probability) for the Estimated Standard Errors of the
Calibration Estimator and the Standard Logistic Regression Estimator for Log Odds Ratios in
the External Population, βE, in the Continuous Covariate Setting for Simulation Parameters








cal basic cal basic cal basic cal basic
Scenario 1 -3 (0.95) 128 (0.00) -7 (0.93) -1 (0.95) -5 (0.94) -1 (0.95) -5 (0.94) 0 (0.95)
Scenario 2 -4 (0.94) 119 (0.00) -7 (0.92) 0 (0.08) -4 (0.94) 0 (0.95) -6 (0.94) -2 (0.95)
Scenario 3
-11 (0.58) 106 (0.00) -6 (0.93) 0 (0.09) -2 (0.95) 1 (0.96) -6 (0.93) -2 (0.95)
-13 (0.11) 65 (0.00) -6 (0.93) 0 (0.08) -4 (0.94) -1 (0.95) -4 (0.94) 0 (0.95)
-14 (0.01) 38 (0.00) -6 (0.93) 1 (0.08) -5 (0.93) -1 (0.95) -6 (0.94) -2 (0.95)
-5 (0.91) 83 (0.00) -2 (0.43) 0 (0.76) -1 (0.95) 1 (0.95) -5 (0.94) 0 (0.95)
-9 (0.92) 149 (0.00) -8 (0.00) -1 (0.00) -4 (0.94) 1 (0.95) -17 (0.90) 0 (0.95)
Scenario 4
-12 (0.83) 82 (0.00) -1 (0.92) 0 (0.11) -4 (0.94) 0 (0.95) -5 (0.94) -1 (0.95)
-5 (0.03) 54 (0.00) 2 (0.90) 0 (0.19) -4 (0.94) -1 (0.95) -5 (0.94) -1 (0.95)
-11 (0.17) 49 (0.00) -5 (0.94) 1 (0.15) -2 (0.95) 1 (0.95) -4 (0.94) 0 (0.95)
-13 (0.15) 75 (0.00) -6 (0.93) 1 (0.07) -5 (0.94) 0 (0.95) -7 (0.94) -2 (0.94)
0 (0.87) 107 (0.00) 0 (0.00) 1 (0.03) -7 (0.94) 0 (0.95) -13 (0.91) 0 (0.95)
-1 (0.45) 11 (0.00) -2 (0.81) -1 (0.77) -2 (0.95) -1 (0.95) -4 (0.95) -2 (0.95)
“cal” refers to the calibration estimator
“basic” refers to the standard logistic regression estimator
were quite small, so even a very small amount of bias appears large when presented on
the scale of percent bias. A better indicator of performance of the variance estimator
is to consider the coverage probabilities, which is what we will focus on.
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In Scenario 1, we see that both methods have coverage probabilities hovering
around the appropriate 0.95 level. In this case the point estimates are unbiased so
we would expect the standard deviation estimates to be unbiased as well; however
we do see a bit of bias in the variance estimator for the calibration estimator. This
is most likely due to the fact that these sample sizes are not quite large enough for
the asymptotics of the robust variance estimates to have kicked in yet. In additional
simulations (not shown) we found that this bias shrank as we looked at increasingly
larger sample sizes, supporting the notion that this is a small sample bias.
As we observed in Table 3.5, in Scenarios 2 through 4 there is some degree of
bias in the point estimates of β0 and βx for the calibration estimator. In these
settings where the point estimates are biased, we expect the variance estimator to
show some bias as well. However, even in these cases the coverage probabilities
still seem relatively reasonable, with a few exceptions. In Scenario 2, we see that
there is a large percent bias in the standard deviation estimates, especially when the
risk relationship is reverse, and yet the coverage probabilities for all parameters are
still greater than 90%. In Scenario 3, when the populations have different means
for P (X), the calibration coverage probabilities for βx are still above 90% but the
variance estimates of the intercept βE0 are significantly affected, with unacceptably
low coverage. Conversely, when the populations have different standard deviations for
P (X), the coverage probabilities for βE0 are above 90% while the coverage probabilites
for βEx drop significantly.
In Scenario 4, when the distribution of P (Z|X) differs between the populations,
for the most part the coverage probabilities are still very good, despite the bias in
the point estimates. However, when the means of the distributions are different,
the calibration coverage probabilities for β0 are unacceptably low; and when the
covariance between X and Z is 0 in the sample but non-zero in the true population,
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then the coverage for βx is also quite bad. The calibration coverage probabilities for
βz and βxz remain above 85% for all simulation scenarios, and in most cases hover
very close to the 0.95 level.
Other Observations
In the course of conducting these simulations, we noted the importance of using a
robust variance estimator for the existing model, ΣE, in the variance calculation for
the calibration estimator. Standard logistic regression software in R does not return
the robust variance estimator by default, so it is unlikely that the variance reported
for a published model is the robust variance estimate unless specifically stated. In
practice it may be necessary to contact the researchers who built the existing model
to request the robust variance matrix. For the purposes of calibration, it would be
even better if researchers made it standard practice to publish the robust variance
estimator from the outset.
Our simulation explored the performance of the calibration estimator in great
detail for the setting of building a logistic regression model, calibrated to a published
logistic regression model. This application of the calibration estimator addresses
the motivating problem we described in Example 1 of 3.2. However, the theoretical
results we’ve shown for the calibration estimator hold generally and can be applied
to calibrate other types of models as well. For instance, to address the motivating
problem we laid out in Example 2 of 3.2, in Appendix E we show how to use calibration
estimator to calibrate the Cox Proportional Hazards model.
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3.6 Conclusions and Practical Recommendations
We proposed the use of a calibration estimator as a way of incorporating relevant ex-
ternal information when building a new or updated model with the aim of improving
the efficiency and representativeness of the model. The estimator had not previously
been studied in the setting where the sample data and the external information are
representative of different populations, so we evaluated its performance in that con-
text, both analytically and numerically. We identified a mapping, given by equation
3.3, that plays a key role in whether or not the calibration estimator produces mean-
ingful results when the populations are different. We showed that if the mapping is
common for the two populations, then the calibration estimator is asymptotically un-
biased for the parameters of the external population, up to a Taylor’s approximation.
With further exploration of the mapping, we determined that a critical require-
ment for the mapping to be common, and thus for the calibration estimator to perform
well, is that the conditional distribution of the new risk factors, Z, given the pub-
lished risk factors, X, be the same in the two populations. For a given application,
researchers should carefully consider whether this is the case based on the features of
their particular dataset and the source of external information that is available.
We also found that if the external model is not correctly specified, then the per-
formance of the calibration estimator is sensitive to differences in the distribution of
the published risk factors, X, and is especially impacted when the degree of variation
differs between in the two populations. Thus, we recommend calibrating to satu-
rated models when possible. In general, calibrating to external information in a form
that is most saturated will reduce the impact that any potential differences in the
distribution of the published risk factors, X, would have on the resulting model.
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3.7 Future Work
In the course of evaluating the calibration estimator we identified some weaknesses
that have inspired avenues of future work in this area. As we have discussed, we
found that the performance of the calibration estimator depends on whether the
distribution of P (Z|X) in the internal data is representative of the distribution in
the external population of interest, and in cases where the external model is not
correctly specified, on P (X) as well. Unfortunately, these distributions contribute
to the calibration implicitly in a way that does not make it possible to incorporate
better estimates of P (Z|X) and P (X), perhaps from survey data, in situations where
it would be necessary. This inspired us to consider ways to overcome that limitation,
while still making use of the powerful mapping that relates parameters of the new
model to the parameters of the existing model.
In the future, we plan to explore a constrained maximum likelihood approach that
makes use of the key mapping given by equation (3.3) as a constraint in the likelihood.
The mapping will still involve the distributions P (Z|X) and P (X), but an advantage
of this approach is that one would have the option of incorporating estimates of those
distributions from other sources, such as survey data, into the constraint.
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3.8 Appendix A: The Mapping
Here we will derive the implicit mapping q(·) that relates the parameters of the full
model with the parameters of the reduced model. We begin with the identity
E [ U(Y |X; θ) ] = 0, which holds for every true value θ.∫
Y,X
U(Y |X; θ) P (Y,X) dY dX = 0
∫
Y,X,Z
U(Y |X; θ) P (Y,X,Z) dY dXdZ = 0
∫
Y,X,Z
U(Y |X; θ) P (Y |Z,X) P (Z|X) P (X) dY dXdZ = 0
By incorporating the full model parametrized by β for P (Y |Z,X), we establish an
implicit relationship with θ defined by∫
Y,X,Z
U(Y |X; θ) f(Y |Z,X; β) P (Z|X) P (X) dY dXdZ = 0











12. We begin with the implicit mapping











f(Y |Z,X; β) P (Z|X)dZ
]
P (X) dY dX
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To temporarily simplify the notation, express this as 0 =
∫
Y,X
A · B · P I(X), letting
A = U(Y |X, q(βI)) and B =
∫
Z
f(Y |Z,X; β) P (Z|X). Take the derivative of both












































ST (Y |Z,X; β) f(Y |Z,X; β) P (Z|X).













f(Y |Z,X; β) P (Z|X)
]
· P (X) +
∫
Y,X
U(Y |X, qT (β)) ·
(∫
Z
ST (Y |Z,X; β) f(Y |Z,X; β) P (Z|X)
)
· P (X).
By recognizing that these integrals represent expectations over the population, we











U(Y |X, q(β))ST (Y |Z,X; β)
]
.
When considering the mapping in the internal population, these population expecta-














































Recall that the matrices d1, c11, and d2, c22 are representations of the Fisher’s infor-
mation for β and θ respectively. Thus, we can incorporate robust variances for the























































 since d1 = c11.











Assuming that c22 is invertible and applying these rules to the second expression of
the overall matrix c, we see that
det[c] = det[c22] · det[d1 − c12c−122 cT12] = det[d1] · det[c22 − cT12d−11 c12].
However, from (3.9) we know that det[c22 − cT12d−11 c12] = 0, meaning that
det[c22] · det[d1 − c12c−122 cT12] = 0. (3.10)
Since we assume c22 is invertible, det[c22] 6= 0. Thus, in order for (3.10) to be satisfied
it must be the case that det[d1 − c12c−122 cT12] = 0, which implies that d1 = c12c−122 cT12.
3.11 Appendix D: Mapping in a Special Case
Here we derive the mapping q(·) in the special case where the reduced model is cor-
rectly specified, in addition to the full model. In this case, we begin with the identity
∫
Y
g(Y |X; θ) = 1, which holds for all θ and X.
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U(Y |X; θ)g(Y |X; θ) = 0.
Under the assumption that the reduced model is correctly specified, it is the case that
g(Y |X; θ) =
∫
Z






f(Y |X,Z; β)P (Z|X)dZ
]
= 0
defines the mapping for each value of X.
.
3.12 Appendix E: The Calibration Estimator
Applied to the Cox Proportional Hazards
Model
In the simulation section, we implemented the calibration estimator in the public
health context presented in Example 1, where the objective was to fit a logistic
regression model on case-control data while calibrating to an existing reduced model
built from a large cohort. Now we turn our attention to Example 2 and detail how
to use the calibration estimator to estimate the baseline hazard function for the Cox
proportional hazards model, λ(t|X) = λ0(t)eXβ, such that it is marginally calibrated
to registry incidence rates.
Suppose we have data (Xi, Ti, δi) from a prospective cohort on covariates X,
event time T and censoring indicator δ on N individuals in the United States, which
we want to use to fit the the Cox proportional hazards model. Recall that λ(t|X) =
P (T = t|T ≥ t,X) and the baseline hazard λ0(t) = P (T = t|T ≥ t,X = 0). The
SEER cancer registry monitors the US population, and is an excellent source of
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precise, representative estimates of cancer incidence, P̂ (T = t|T ≥ t) = λ̂m(t). To
conceptualize this problem in the framework we have proposed, we think of the model
we want to fit, λ(t|X), as the full model, and the marginal model λm(t) that does
not incorporate covariates as the reduced model. Thus, the incidence rates from the
SEER registry can be thought of as an existing, reduced model toward which to
calibrate.
As in Section 2.3.1, we define the hazard functions by parameters at each observed
event time tq for q=1,...,Q, as follows:
λ0(t) =

λ0q for tq = t
0 else
 ; λm(t) =







λ0qI {t0q = t} ; λm(t) =
Q∑
q=1
λmqI {tmq = t} .



















are the maximum likelihood es-
timators estimated in the sample, with dq denoting the number of observed events
at time tq and nq are the number at risk at that time. λ̂
E
mq are the incidence esti-
mates provided by the registry at each time. The expressions for Fisher’s information






































Note that because we have defined these functions by a parameter at each observed
event time, the matrices D1, D2, C12 and C22 all have dimension J by J , where J
is the number of observed event times. Similarly, the variance matrix ΣE for the
“existing model” parameters would theoretically also be J by J . However, in the
case where the incidence rates come from a cancer registry as large as SEER, it may
be reasonable to treat the λEmq’s as known, and effectively without variation, ΣE = 0.
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Chapter 4
Data Applications and Results
4.1 An Absolute Risk Model for Breast Cancer
4.1.1 Introduction
Thus far, we have reviewed statistical methods for building absolute risk models and
developed some novel methodologies that extend the existing methods to accommo-
date disease subtypes in settings where data sources may be completely or partially
missing the disease characteristics that define subtype. We then discussed a method
for building risk models that are calibrated to existing published models or to disease
registries. Having discussed the statistical methods at length, in this chapter we will
apply the methods in a real data setting to develop absolute risk models for breast
cancer.
We will begin by developing a model for overall invasive breast cancer based on
known breast cancer risk factors and genetic information from 24 single nucleotide
polymorphisms (SNPs) using prospective cohort data. Our goal is to use the absolute
risk model to project the distribution of breast cancer risk in ages 30-70 for the US
population. This provides an opportunity to contrast the results with those from the
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subtype-specific model, which is built based on case-control studies in the BCAC.
Additionally, we plan to use the risk model to evaluate the potential impact that
population-wide risk factor modification would have on the distribution of risk in the
United States. Since many standard risk factors for breast cancer are not modifiable,
a woman at high risk based on non-modifiable risk factors can only reduce her risk so
much, even by adopting the lowest risk health behaviors. With this in mind, we will
investigate the impact of risk factor modification for hormone replacement therapy
use, body mass index, alcohol consumption, and smoking behaviors on overall breast
cancer risk within strata defined by non-modifiable risk.
4.1.2 Materials and Methods
Study Population
We analyzed data on a total of 17,176 invasive breast cancer cases and 19,860 controls
from 8 prospective cohort studies participating in the Breast and Prostate Cancer Co-
hort Consortium (BPC3), including 6 American cohorts (CPSII, NHS, WHS, PLCO,
MEC, and WHI), 1 European cohort (EPIC), and 1 Australian cohort (MCCS)
(Hunter et al., 2005; Husing et al., 2012). The observations contributed by each
cohort are given in Table 4.1. These cohorts contributed information on known
breast cancer risk factors including first degree family history, age at menarche, par-
ity, age at first full term birth, menopausal status, age at menopause, height in cm,
body mass index (BMI), alcohol consumption in g/day, smoking status, and hormone
replacement therapy (HRT) use. Four binary HRT variables included information on
ever use of HRT, ever use of estrogen only HRT, ever use of combined estrogen and
progestin HRT, and current use of HRT. Additionally, these cohorts included genetic
information on 24 SNPs. We excluded 42 cases and 45 controls with risk factor values
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that differed by more than 4 standard deviations from average after transforming the
risk factors to be approximately normal.
Statistical Methods
Completeness of the breast cancer risk factors varied by cohort and is presented in
Supplemental Table 4.1. We imputed missing values for all risk factors sequentially, in
order of increasing missingness. We constructed each imputation model conditional
on case-control status, outcome age, cohort, and all completed variables that were
significantly associated with the risk factor being imputed. These imputation models
also included any significant two-way interactions between the variables included in
the model. In cases where a cohort had no data on a given variable from which to
build the imputation model, such as for some HRT variables, the imputation was
performed from the model built on the cohort thought to be the most similar based
on related variables. We fit logistic models for the association between case-control
status and each variable, adjusted for age and cohort, before and after imputation to
verify that none of the estimated effects changed by more than 10%, and found that
most differed by less than 2% before and after imputation.
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Different cohorts also had different patterns of missing data for each of the 24
SNPs in the dataset. Within each cohort, we imputed missing data for each SNP for
which there was data from an imputation model conditional on case-control status,
family history, and an interaction between the two. In cases where a cohort had no
data on a given SNP, we did not attempt to impute a value for that SNP. We planned
to incorporate SNP data in the absolute risk model through a single polygenic risk
score (PGRS) equal to the sum of estimated log odds ratios for each SNP multiplied
by the observed SNP profile for each individual. For the SNPs entirely missing in a
given cohort, we imputed the missing component of the polygenic risk score (rather
than each individual SNP), taking family history into account using the methods of
Chatterjee et al. (2013).
To explain further, to construct a PGRS for the BPC3 data, we fit a logistic
regression model with all 24 SNPs, adjusted for family history, categorical age, and
cohort for individuals with complete data on those variables to obtain estimates of
the log odds ratio parameters for each SNP: β̂1, ..., β̂24. We then used those estimates
to compute the PGRSi =
24∑
j=1
β̂j ·Gij for each person using their own particular SNP
profile, Gi. However, if a cohort was fully missing data on a given set of SNPs, the
PGRS could be decomposed into a component that could be directly computed from















Rather than attempt to impute values for each missing SNP, indexed by k, we instead
imputed the missing component of the PGRS, γi, still using the empirical SNP data
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from each individual for SNPs that did have data, indexed by j. We know that γi is a
sum of random variables so we can impute from normal distributions with appropriate
mean and variance. Chatterjee et al. (2013) detail how to specify the parameters of
the imputation in a way that accounts for case-control status and family history.
The method relies solely on estimates of the log odds ratios and allele frequencies
for the missing SNPs along with an estimate of the log odds ratio for family history,
all of which we obtained from the completed data (Chatterjee et al., 2013). For the
purposes of comparison, we created a fully simulated PGRS based on 24 SNPs by
imputing the entire PGRS, not just the missing component. Using this method, we
also created a simulated PGRS based on 86 SNPs, adding an additional 62 SNPs
found to be associated with breast cancer in the published literature, with log odds
ratios and allele frequencies estimated in the BCAC data.
Using the imputation methods described, we created 5 imputed datasets for anal-
ysis. To build the absolute risk model, we employed the methods pioneered by (Gail
et al., 1989), the details of which we reviewed in Chapter 2. We estimated the hazard
ratio component of the model using standard logistic regression adjusted for quintiles
of outcome age and cohort. We estimated the attributable risk among the cases using
the Bruzzi method, by computing one minus the average of the inverse relative risks
among the cases (Bruzzi et al., 1985). We combined the estimated attributable risk
with marginal hazard rates of overall breast cancer in the SEER registry to obtain
baseline hazard rates. Having constructed the absolute risk model, we then used
it to predict risk of breast cancer among the controls to obtain an estimate of the
distribution of risk for ages 30-70 in the population.
When predicting risk over the age interval 30-70, all women are initially pre-
meopausal (with no HRT use) and become postmenopausal at their recorded age at
menopause. In addition to menopausal status, at this time the variables reflecting
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HRT use are changed from “never” to the actual HRT use behaviors of the women
for whom risk is to be predicted. For women who are premenopausal, the age at
menopause and HRT use variables are not defined. For the purposes of projecting
risk for these women, we use an age at menopause of 50 (the median among post-
menopausal women in the dataset) and we impute HRT use variables from a model
fit on the postmenopausal women for whom the HRT variables are known. We con-
structed the absolute risk model and predicted risk for each of the 5 imputed datasets
and averaged the results.
4.1.3 Results and Discussion
To determine the form of the hazard ratio component of the absolute risk model, we
performed a number of exploratory analyses. To evaluate whether the effect of each
risk factor could be modeled in a linear fashion, we fit generalized additive models
relating case-control status to each continuous variable, adjusted for age and cohort
(Hastie and Tibshirani, 1990). The models allowed us to look at flexibly modeled,
smoothed covariate effects to ascertain whether linear modeling was appropriate. In
general we found non-linearity in the effects and thus chose to take a more non-
parametric approach, including categorical versions of the continuous risk factors
in the model. We evaluated heterogeneity in the effects across cohorts by creating
forest plots and testing for differences in effect size. We did not see statistically
significant heterogeneity in the effects by study, except for the age at first full term
birth (AFFTB) variable. In this case, all studies were qualitatively consistent in
showing that greater AFFTB increased risk but differed in the estimated effect size.
We also evaluated whether to include an interaction between the PGRS and any
of the risk factors. We tested interactions between the PGRS and each covariate,
modeled continuously to reduce the degrees of freedom and increase the power for
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detecting interaction. We first tested interactions between the PGRS and each con-
tinuous covariate, adjusting for age and cohort, for the middle 90% of the PGRS.
We separately tested interaction in the extremes of PGRS (defined by the upper and
lower 5th percentiles) separately, by including a binary indicator of “extreme” (rel-
ative to the middle) and testing the interaction with each continuous covariate. We
also looked at forest plots and performed statistical tests to evaluate heterogeneity
in the effect size for each continuous covariate across deciles of the PGRS. Across
these evaulations we did not see consistent evidence of interaction between PGRS
and any risk factor and thus did not include any interactions with PGRS. Previous
studies have found that the effect of BMI on breast cancer risk is strongest among
postmenopausal never-HRT users (Lahmann et al., 2004; Morimoto et al., 2002; Lah-
mann et al., 2003). We observe this in the BPC3 data as well and accordingly we
include an interaction between BMI and HRT in the model.
Based on our initial analyses, we formulated a fully-adjusted model with main
effects for the categorical covariates and an interaction between deciles of BMI and
ever use of HRT, along with deciles of PGRS, and adjustment for quintiles of age
and cohort. Supplemental Table 4.2 contains the hazard ratio estimates from this
model with the PGRS based on empirical genotype data for 24 SNPs, which are
consistent with previous associations for the standard breast cancer risk factors. Table
4.2 compares the hazard ratio estimates for deciles of the PGRS based on empirical
genotype data for 24 SNPs with the hazard ratio estimates for deciles of the simulated
PGRS for 24 SNPs in the fully-adjusted model. The estimates correspond closely,
providing support for our use of the simulated PGRS for 86 SNPs going forward. We
evaluated the discriminatory accuracy of a number of models, including those with
risk factors alone, PGRS alone, and risk factors and PGRS together for both the
PGRS based on empirical genotype data for 24 SNPs and the simulated PGRS for
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Table 4.2: Comparison of Estimated Hazard Ratios for Deciles of PGRS, for PGRS




PGRS Decile 1 1 1
PGRS Decile 2 1.19 1.21
PGRS Decile 3 1.33 1.38
PGRS Decile 4 1.43 1.47
PGRS Decile 5 1.58 1.59
PGRS Decile 6 1.66 1.75
PGRS Decile 7 1.78 1.89
PGRS Decile 8 2.05 2.02
PGRS Decile 9 2.26 2.27
PGRS Decile 10 2.80 2.84
Family History 1.41 1.38
86 SNPs. Figure 4.1 shows the Receiver Operating Characteristic (ROC) curves and
the area under the ROC curve (AUC) for these models (Hanley, 1989). We find that
the best discriminatory accuracy is provided by a model with risk factors and the
simulated PGRS for 86 SNPs, with AUC=0.654.
We predicted absolute risks among controls for ages 30-70 from two fully-adjusted
models, one with the PGRS based on empirical genotype data for 24 SNPs and the
other with the simulated PGRS for 86 SNPs. Table 4.3 presents average predicted
risk within deciles of risk for these two fully-adjusted models. These results show
increased risk stratification for the 86 SNP model, particularly for those at highest
risk. Figure 4.2 shows the distribution of predicted absolute risks for ages 30-70
for the fully-adjusted model with simulated PGRS based on 86 SNPs, along with the
percentage of the population projected to exceed referent risk thresholds.
Ideally, individuals at high risk of disease could seek to reduce their risk by mod-
ifying their behaviors. Unfortunately, most known breast cancer risk factors such as
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0 Risk Factors Alone,        AUC= 0.587
24 SNPs Alone,            AUC= 0.585
Risk Factors + 24 SNPs, AUC= 0.62
86 SNPs Alone,            AUC= 0.631
Risk Factors + 86 SNPs, AUC= 0.654
Table 4.3: Average Absolute Risk of Breast Cancer in Ages 30-70 from Two Fully-
Adjusted Models, with the PGRS from Empirical Genotype Data for 24 SNPs and
the Simulated PGRS for 86 SNPs, by Risk Decile
Among Controls
24 SNPS 86 SNPS
Risk Decile 1 4.19 3.15
Risk Decile 2 5.36 4.35
Risk Decile 3 6.17 5.29
Risk Decile 4 6.93 6.20
Risk Decile 5 7.69 7.15
Risk Decile 6 8.53 8.21
Risk Decile 7 9.52 9.45
Risk Decile 8 10.77 11.13
Risk Decile 9 12.60 13.67
Risk Decile 10 16.98 19.58
Overall 8.87 8.82
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Figure 4.2: Distribution of Absolute Risk of Breast Cancer in Ages 30-70 from Fully-
Adjusted Model with Simulated PGRS for 86 SNPs
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family history, reproductive factors, and genetic factors are not modifiable. In fact,
in our absolute risk model the only modifiable risk factors are alcohol consumption,
HRT use, BMI, and smoking status. We evaluated how modifying these risk factors
to their lowest risk levels, individually and simultaneously, impacts the projected risk
distribution for ages 30-70 using the fully-adjusted model with 86 SNPs. In particular,
we computed two quantities to quantify the risk reduction associated with modifying
risk factors: percent total cancer (PTC) reduction and percent preventable cancer
(PPC) reduction.
We defined PTC as the difference between the probability of disease in the pop-
ulation and the probability of disease for those with lowest risk modifiable factors,
M0, as a proportion of the overall probability of disease; mathematically, PTC =
[P (D)− P (D|M0)] /P (D). We then partitioned the PTC by categories defined by
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[P (D|G)− P (D|G,M0)]P (G)
]
/P (D).
Thus, the percent total cancer reduction that would occur by reducing all modifiable
risk factors to the lowest risk levels in a particular non-modifiable risk category, G′,
is given by
PTC(G′) =
[P (D|G′)− P (D|G′,M0)]P (G′)
P (D)
.
We defined percent preventable cancer similarly, but with P (D) − P (D|M0) in the
denominator in order to measure the risk reduction as a proportion of the possible
reduction that could be achieved if the entire population reduced modifiable risk
factors to the lowest risk levels.
PPC(G′) =
[P (D|G′)− P (D|G′,M0)]P (G′)
P (D)− P (D|M0)
.
We computed P (D|G) within strata defined by the quintiles of non-modifiable risk
by using the absolute risk model to predict risk for the covariate profiles of controls
in the dataset. To compute P (D|G′,M0) we predicted risk for the same covariate
profiles but set the modifiable risk factors to their lowest risk levels. Using these
quantities, we computed the proportion of all breast cancers that would be prevented
by modification of the risk factor (PTC) and the percent that would be prevented
if one were to target risk factor modification to those in a given quintile of non-
modifiable risk (PPC).
Table 4.4 presents these results. We see that targeting all risk factors simulta-
neously is projected to result in a 32% reduction of breast cancer in the population,
while targeting HRT-use alone would only result in a roughly 17% reduction overall.
We also see that by targeting risk factor modification efforts to those in the upper
20th percentile of non-modifiable risk, roughly 35% of the preventable breast cancers
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Table 4.4: Percent Preventable and Percent Total Breast Cancer Reduction for Ages
30-70 from Modification of Risk Factors by Non-Modifiable Risk Group, Based on
Fully-Adjusted Model with Simulated PGRS for 86 SNPs
Non-Modifiable Alcohol HRT BMI Smoking Simultaneous
Risk %P %T %P %T %P %T %P %T %P %T
Quintile 1 9.3 0.71 9.1 1.54 10.2 0.87 9.6 0.38 9.6 3.10
Quintile 2 14.0 1.07 13.8 2.34 14.5 1.23 14.3 0.57 14.2 4.58
Quintile 3 18.0 1.38 18.1 3.06 18.4 1.57 18.2 0.73 18.2 5.89
Quintile 4 23.4 1.79 23.4 3.94 23.0 1.96 23.4 0.93 23.3 7.52
Quintile 5 35.4 2.71 35.5 6.00 34.0 2.90 34.5 1.38 34.8 11.25
Overall – 7.66 – 16.89 – 8.53 – 3.99 – 32.33
%P refers to percent preventable breast cancer reduction
%T refers to percent total breast cancer reduction
might be prevented. This indicates that targeted prevention strategies may yield a
greater breast cancer reduction for the same resources invested. However, this also
indicates that a considerable proportion of preventable breast cancer falls outside the
highest non-modifiable risk group so there is reason to pursue broader prevention
strategies as well.
Within categories defined by non-modifiable risk there is significant variability in
overall breast cancer risk, depending on the specific risk factors, both modifiable and
non-modifiable, of each woman in that group. Figure 4.3 presents the distribution of
breast cancer risk in ages 30-70 by non-modifiable risk group based on results from
the fully-adjusted model with simulated PGRS for 86 SNPs. It is clear that the higher
risk non-modifiable groups have a greater degree of stratification in breast cancer risk
than the lower risk groups. This as an important, though perhaps under-appreciated,
consequence of modeling risk with a logistic regression model, which is formulated
such that risk factors act multiplicatively on risk. A model with no interaction on the
relative risk scale does result in an interaction on the scale of risk differences, which
is what we consider when working with absolute risk. Thus, even though there is
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Figure 4.3: Distribution of Absolute Risk of Breast Cancer in Ages 30-70 by Non-
Modifiable Risk Group, Based on Fully-Adjusted Model with Simulated PGRS for 86
SNPs




































no interaction between the modifiable factors and the non-modifiable factors in our
logistic model, we see an interaction on absolute risk scale.
This has important ramifications for disease prevention efforts. Though the rela-
tive risk of modifying a given risk factor may be the same for two women, their risk
differences may be drastically different depending on their other risk factors, with
one receiving a substantially greater benefit. This presents a compelling reason for
considering disease prevention in public health through the lens of absolute risk.
4.1.4 Conclusions and Future Work
We built two absolute risk models for invasive breast cancer from prospective co-
hort data in the BPC3 data that incorporated known breast cancer risk factors and
polygenic risk scores based on 24 and 86 SNPs respectively. Having developed these
absolute risk models, we projected the distribution of breast cancer risk in the BPC3
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controls for ages 30-70 and found that approximately 1.1% had a breast cancer risk
exceeding 20%. It is possible that the covariate profiles in BPC3 represent women
with generally lower risk health behaviors, in which case the projected risk distribu-
tion would underestimate the distribution of risk in the general US population. In
future work, we plan to obtain nationally representative covariate distributions from
the National Health and Nutrition Examination survey (NHANES) to use for pro-
jecting risk, and compare the resulting risk distribution to that projected from the
BPC3 data.
We used the absolute risk model to investigate the impact of population-wide
modification of alcohol consumption, smoking behavior, body mass index, and use of
hormone replacement therapy, alone and simultaneously, on breast cancer risk. We
evaluated the reduction in breast cancer risk that could be achieved by targeting risk
factor modification efforts to women at high risk based on non-modifiable risk factors,
such as genetics or defined reproductive risk factors. While we found that targeting
risk reduction efforts to the highest risk group based on non-modifiable factors would
result in greater breast cancer reduction than intervening in the population at random,
we found that much of the preventable breast cancer risk was outside of that high
risk group so broader intervention efforts are needed as well.
In the future, we plan to work with collaborators to develop an absolute risk
model for invasive breast cancer in the UK. The model will incorporate the hazard
ratios presented here, fit on the BPC3 data. However, for the UK absolute risk
model we will base the estimates of attributable risk on a risk factor distribution that
is representative of women in the UK. Additionally, we will calibrate the model to
breast cancer rates from the UK. We plan to validate the model in data from the UK
Breakthrough Generations Study.
In the next section, we develop subtype-specific absolute risk models for subtypes
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of breast cancer defined by estrogen receptor status in the US population using data
from the BCAC consortium of case-control studies. We can obtain estimates of breast
cancer risk from the sum of the subtype-specific risks provided by the models. In the
future, we also plan to build an absolute risk model for overall breast cancer directly
from the BCAC data. We will compare the projected risk distribution of overall
breast cancer from BCAC to these BPC3 results. Through this comparison, we will
investigate differences that may arise due to building the absolute risk model from
a consortium of case-control studies as opposed to a consortium of cohorts. We will
also compare the risk stratification produced by the simulated PGRS for 86 SNPs
with that from a PGRS based on empirical genotype data on 77 SNPs in the BCAC
data.
4.2 Absolute Risk Models for Breast Cancer
Subtypes Defined by Estrogen Receptor
Status
4.2.1 Introduction
In this section, we make use of the methods developed in Chapter 2 to build absolute
risk models for subtypes defined by estrogen receptor (ER) status. ER+ and ER-
breast cancer subtypes are quite distinct. In general, ER+ breast cancer has later
age of onset compared with ER- breast cancer (Anderson and Matsuno, 2006). ER+
breast cancer is more common, comprising 77% of breast cancers for which ER status
is known in SEER (Jatoi et al., 2007). Many risk factors have been identified for
ER+ breast cancer, including all reproductive factors included in our previous model
for overall breast cancer, but few have been identified for ER- breast cancer (Ma
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et al., 2006). ER+ breast cancer is thought to be hormonally-driven, and a number
of treatments have been developed, resulting in a generally more favorable prognosis
for ER+ compared to ER- breast cancer (Elledge et al., 1994). The most well known
of these is tamoxifen, which has also been used as a preventative treatment for ER+
breast cancer (Moyer et al., 2013; Fisher et al., 1998). However, use of tamoxifen has
been shown to be associated with adverse events, including stroke, and thus should
only be administered as a preventative treatment to women who are expected to
derive the most benefit, those at high levels of risk for ER+ breast cancer (Bushnell
and Goldstein, 2004). A subtype-specific absolute risk model for ER+ breast cancer
can be used to identify women who exceed thresholds of risk for which the benefits
of preventative breast cancer treatments outweigh the harms.
In the following sections, we develop subtype-specific risk models for ER+ and
ER- breast cancer with the goal of estimating distributions of breast cancer risk for
each subtype in the US population, and producing estimates of overall breast cancer
risk from the sum of the subtype-specific risks. We then examine and compare the
degree of risk stratification produced by these models for ER+, ER-, and overall
breast cancer.
4.2.2 Materials and Methods
Study Population
We analyzed data on a total of 36,018 cases of invasive breast cancer and 36,155
controls from 27 case-control studies in the Breast Cancer Association Consortium
(BCAC), 10 of which were classified as population based. The BCAC constortium
pools information across many large breast cancer studies in order to provide a re-
source for comprehensive investigation of breast cancer risk factors, in particular
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genetic risk factors (Breast Cancer Association Consortium, 2006; Yang et al., 2011b;
Milne et al., 2010; Fasching et al., 2012; Nickels et al., 2013). These studies provide
information on standard breast cancer risk factors, including first degree family his-
tory, parity and age at first full term birth, age at menarche, menopausal status and
age at menopause, height, body mass index (BMI), alcohol consumption, smoking
behavior, and hormone replacement therapy (HRT) use. Some studies provided more
detailed information on HRT, including data on ever use of HRT, current use of any
HRT, current use of estrogen-type HRT, and current use of combined estrogen and
progestin-type HRT. In addition, all included studies provided genotype data on 77
SNPs previously found to be associated with breast cancer. These SNPs were geno-
typed using a custom Illumina iSelect genotyping array known as iCOGS, designed
as part of the Collaborative Oncological Gene-Environment Study (COGS) to test
genetic variants related to breast cancer (Sakoda et al., 2013; Bahcall, 2013). We
restricted our analysis dataset to those with iCOGS data, known female sex, and re-
ported European ethnicity. We excluded studies that were classified as family-based
or of mixed design.
For cases, additional information was provided on tumor characteristics, indicat-
ing whether the tumor was positive, negative or unknown for each of the following
markers: estrogen receptor (ER), progesterone receptor (PR), and human epidermal
growth factor receptor 2 (HER2). Specifically, the 36,018 cases were distributed as
ER+ (65.6%), ER- (15%), unknown ER status (19.4%), with PR+ (48.4%/0, PR-
(21.2%), unknown PR status (30.4%); and HER2+ (8.2%/0, HER2- (43.8%), un-
known HER2 status (48.0 %). Here, we focus on developing an absolute risk model




To be consistent with previous analyses of the BCAC data, we chose to model
as categorical the variables family history (no/yes), parity (0/1/2/3/4+), smoking
(no/current), and menopausal status and HRT (Premeno, Postmeno Never HRT use,
Postmeno Former HRT use, Postmeno Current Non-E-Type HRT use, Postmeno Cur-
rent Only E-Type HRT use, and Postmeno Current Any EP-Type HRT use. We chose
to model as continuous the variables age at menarche divided by 2, age at first full-
term birth divided by 5, age at menopause, alcohol consumption divided by 10, and
height and bmi divided by 5. All continuous variables were centered by subtracting
the median value.
In defining these variables, we encountered two types of missing data. We observed
“structural missing” data when studies were entirely missing a given covariate. Any
study with fewer than 200 cases or 200 controls with data for a given covariate were
treated as structurally missing for that covariate. In other cases, studies had mostly
complete data for a given covariate but were “randomly missing” some observations.
Due to the large number of studies, we did not attempt to build models to impute
missing covariate values. Instead we included missing categories for each covariate,
paying careful attention to model the variables with missing categories such that the
resulting model parameters were interpretable. Those with missing data on any of
the 77 genotyped SNPs comprised less than 4% of the study population and were
excluded from the analysis.
To build absolute risk models for ER+ and ER- subtypes, we employed the meth-
ods described in Chapter 2. In particular, we estimated the hazard ratio component
of the model using the reparametrized multinomial model with the ER+ subtype as
referent. A strength of this method is that cases contribute to estimation even when
ER status is unknown. Additionally, because ER+ is the referent group, a study is
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not required to have controls to contribute to the effect estimation. This makes it
possible to include all cases from hospital based studies, that may not have repre-
sentative controls. We will refer to this method as “full data analysis” (FDA). Table
4.5 gives the sample sizes included in FDA by study, with cases differentiated by ER
status.
Alternatively, one could perform a “complete case analysis” (CCA) and estimate
the model for each subtype individually using standard logistic regression methods,
excluding cases for which the ER status is unknown. To contribute to the CCA,
studies must have good controls, which further restricts the analysis to data from
population based studies. Table 4.6 gives the sample sizes included in CCA for
subtypes defined by ER status. Comparing Table 4.5 and Table 4.6, we see that
FDA allows the model to be fit from roughly five times the number of cases compared
to CCA.
We estimate subtype-specific baseline hazard rates for the absolute risk models
from the marginal SEER incidence rate for overall breast cancer in conjunction with
estimates of attributable risk and observed subtype proportions in the data. We
estimated attributable risk from cases with complete covariates in 4 time intervals,
defined separately for each subtype by the quartiles of outcome age using the Bruzzi
formula (Bruzzi et al., 1985). We estimated subtype proportions in 4 time intervals
defined by outcome age as well. For ER+ and ER- subtypes, one could instead choose
to calibrate to marginal subtype-specific hazard rates directly, which are available in
SEER. This is generally a more optimal strategy; however, here we choose to estimate
the subtype proportions to provide a real data example of the methods presented in
Chapter 2 and to demonstrate what one would do if the subtypes of interest were
such that subtype-specific rates were not provided by SEER.
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Table 4.5: BCAC Sample Sizes Contributing to Full Data Analysis in Multinomial
Model, Overall and by Study
Controls ER+ ER- ER Missing
Total 7480 23624 5613 6974
ABCFS 551 456 261 73
ABCS 0 561 195 397
BBCC 0 456 82 16
BIGGS 0 474 146 173
BSUCH 0 531 152 132
CECILE 999 743 130 27
CGPS 0 1919 357 582
CTS 71 0 68 0
ESTHER 502 303 98 71
GENICA 427 328 119 18
HMBCS 0 35 8 645
KBCP 251 288 89 34
LMBC 0 2069 378 169
MARIE 1778 1279 370 7
MCBCS 0 1271 250 25
MCCS 511 352 119 143
MEC 0 412 87 206
MTLGEBCS 0 421 64 4
NBCS 0 617 199 44
NBHS 118 0 125 0
OBCS 0 403 97 0
ORIGO 0 211 68 56
PBCS 424 519 0 0
pKARMA 0 3588 664 301
SASBAC 1378 663 144 356
SBCS 0 358 104 289
SEARCH 0 5130 1170 2796
SZBCS 0 149 51 103
UKBGS 470 88 18 307
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Table 4.6: BCAC Sample Sizes Contributing to Complete Case Analysis in Separate
Logistic Models, Overall and by Study
Study Controls ER+ Study Controls ER-
Total 7291 5019 Total 7056 1541
ABCFS 551 456 ABCFS 551 261
CECILE 999 743 CECILE 999 130
ESTHER 502 303 CTS 71 68
GENICA 427 328 ESTHER 502 98
KBCP 251 288 GENICA 427 119
MARIE 1778 1279 KBCP 251 89
MCCS 511 352 MARIE 1778 370
PBCS 424 519 MCCS 511 119
SASBAC 1378 663 NBHS 118 125
UKBGS 470 88 SASBAC 1378 144
UKBGS 470 18
4.2.3 Results and Discussion
We modeled the hazard ratios for each subtype from the FDA multinomial regression
model with main effects for the covariates, an interaction between continuous BMI and
menopausal status and HRT use, and 77 SNPs adjusted for deciles of age, study, and
9 principle components scores to account for population substructure. For purposes of
comparison, we fit the same models using CCA in separate logistic regression models.
The estimated hazard ratios for the covariates are given in Table 4.7 and the estimated
hazard ratios for the SNPs are given in Supplemental Table 4.3. In general, the point
estimates for FDA and CCA are consistent with one another for both subtypes, with
the exception of the association between parity and ER- breast cancer. As we would
expect, FDA is more efficient than CCA, with tighter confidence intervals. Testing
statistical significant of the SNP effects in the FDA model finds 47 of the 77 SNPs
to be significantly associated with ER+ breast cancer, where with CCA only 44 are
significant. Similarly, for ER- breast cancer FDA finds that 23 SNPs are statistically
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Table 4.7: Covariate Hazard Ratios (HR) and 95% Confidence Intervals (CI) for Fully-Adjusted
Models of ER+ and ER- Breast Cancer, with Results from FDA and CCA
ER+ ER-
FDA CCA FDA CCA
HR (CI) HR (CI) HR (CI) HR (CI)
Famiy History = No 1 – 1 – 1 – 1 –
Family History = Yes 1.59 (1.39, 1.81) 1.59 (1.38, 1.82) 1.59 (1.38, 1.84) 1.56 (1.26, 1.94)
Family History = Missing 0.92 (0.72, 1.17) 0.91 (0.7, 1.18) 0.55 (0.43, 0.72) 0.74 (0.46, 1.17)
Parity = 0 1 – 1 – 1 – 1 –
Parity = 1 0.95 (0.84, 1.08) 0.91 (0.79, 1.04) 1.06 (0.91, 1.23) 1.47 (1.18, 1.85)
Parity = 2 0.84 (0.75, 0.94) 0.77 (0.68, 0.88) 0.88 (0.77, 1) 1.21 (0.99, 1.48)
Parity = 3 0.71 (0.63, 0.81) 0.68 (0.59, 0.78) 0.72 (0.62, 0.84) 0.94 (0.74, 1.19)
Parity = 4 0.58 (0.5, 0.67) 0.57 (0.48, 0.68) 0.61 (0.51, 0.73) 0.69 (0.52, 0.92)
Parity = Missing 0.41 (0.21, 0.78) 0.36 (0.17, 0.77) 0.24 (0.12, 0.47) 0.4 (0.11, 1.39)
Age Menarche /2 0.93 (0.89, 0.97) 0.93 (0.88, 0.97) 0.93 (0.88, 0.98) 0.93 (0.86, 1.01)
Age Menarche = Missing 0.85 (0.72, 0.99) 0.89 (0.74, 1.07) 0.99 (0.82, 1.19) 0.94 (0.7, 1.26)
Age FFTP /5 1.03 (0.98, 1.08) 1.02 (0.97, 1.08) 0.99 (0.93, 1.04) 0.94 (0.87, 1.03)
Age FFTP = Missing 7.1 (2.38, 21.12) 0.18 (0.02, 2.04) 15.79 (5.27, 47.26) 7.25 (1.04, 50.64)
Age Menopause 1 (0.99, 1) 0.99 (0.99, 1) 1 (0.99, 1.01) 1 (0.98, 1.01)
Age Menopause = Missing 0.87 (0.72, 1.05) 0.87 (0.7, 1.1) 1.08 (0.88, 1.32) 0.77 (0.5, 1.19)
Alcohol /10 1.05 (1.01, 1.09) 1.06 (1.01, 1.1) 1.01 (0.94, 1.08) 1.02 (0.95, 1.09)
Height /5 1.06 (1.03, 1.09) 1.06 (1.03, 1.1) 1.05 (1.01, 1.08) 1.03 (0.98, 1.09)
Height = Missing 0.73 (0.5, 1.08) 0.69 (0.43, 1.1) 1.41 (0.94, 2.1) 0.61 (0.23, 1.61)
BMI /5 1.18 (1.09, 1.27) 1.15 (1.06, 1.25) 1.02 (0.91, 1.16) 1.1 (0.96, 1.26)
BMI = Missing 0.93 (0.69, 1.25) 1.01 (0.72, 1.41) 0.7 (0.49, 0.99) 0.68 (0.37, 1.28)
Smoke = Never, Former 1 – 1 – 1 – 1 –
Smoke = Current 1.09 (0.99, 1.2) 1.09 (0.98, 1.22) 1.03 (0.9, 1.17) 0.98 (0.83, 1.17)
Smoke = Missing 0.22 (0.08, 0.6) 0.31 (0.08, 1.16) 0.38 (0.14, 1.05) 0 (0, Inf)
PostMeno Never HRT USE 1 – 1 – 1 – 1 –
Premenopause 1.46 (1.26, 1.68) 1.57 (1.34, 1.85) 1.09 (0.92, 1.28) 1.27 (1, 1.63)
PostMeno Former HRT Use 0.94 (0.84, 1.05) 0.95 (0.85, 1.08) 0.9 (0.77, 1.04) 0.9 (0.74, 1.1)
PostMeno Current Non-E HRT Use 1.1 (0.94, 1.3) 1.07 (0.89, 1.3) 0.86 (0.69, 1.06) 0.82 (0.6, 1.13)
PostMeno Current Only E HRT Use 1.27 (1.04, 1.55) 1.28 (1.04, 1.58) 0.79 (0.56, 1.11) 0.73 (0.5, 1.05)
PostMeno Current Any EP HRT Use 1.78 (1.54, 2.06) 1.76 (1.51, 2.06) 1.04 (0.82, 1.32) 0.98 (0.74, 1.29)
Meno/HRT = Missing 0.95 (0.61, 1.46) 0.86 (0.52, 1.43) 0.7 (0.45, 1.1) 1.06 (0.48, 2.33)
(BMI/5)*(PostMeno Never HRT Use) 1 – 1 – 1 – 1 –
(BMI/5)*(Premenopause) 0.72 (0.63, 0.81) 0.73 (0.64, 0.83) 0.87 (0.73, 1.03) 0.83 (0.68, 1)
(BMI/5)*(PostMeno Former HRT Use) 0.97 (0.84, 1.12) 0.97 (0.84, 1.14) 1.06 (0.85, 1.33) 0.88 (0.67, 1.16)
(BMI/5)*(PostMeno Current Non-E HRT Use) 0.75 (0.59, 0.95) 0.77 (0.6, 0.98) 0.69 (0.46, 1.05) 0.64 (0.41, 1)
(BMI/5)*(PostMeno Current Only E HRT Use) 0.71 (0.54, 0.93) 0.73 (0.56, 0.96) 0.83 (0.52, 1.34) 0.67 (0.39, 1.15)
(BMI/5)*(PostMeno Current Any EP HRT Use) 0.85 (0.69, 1.04) 0.88 (0.71, 1.1) 1 (0.73, 1.37) 0.94 (0.63, 1.41)
(BMI/5)*(Meno/HRT = Missing) 1.37 (0.45, 4.22) 1.29 (0.34, 4.92) 0.91 (0.26, 3.25) 0.6 (0.04, 8.98)
”FDA” refers to Full Data Analysis
”CCA” refers to Complete Case Analysis
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0 Full Model,        AUC= 0.63
Genes,            AUC= 0.615
Covs,           AUC= 0.563
significant, as opposed to only 18 with CCA.
Figure 4.4 presents ROC curves, computed on 2632 controls and 2177 ER+ and
423 ER- cases with complete data, for FDA models with SNPs alone, covariates
alone, and the main fully-adjusted model for each subtype. For both subtypes, the
SNPs only model provided significantly better discriminatory accuracy than the risk
factor only model. The AUC for the ER+ fully-adjusted model was 0.66 while the
AUC for the ER- fully-adjusted model was 0.63. Figure 4.5 presents the ROC curves
for predicting risk of overall breast cancer based on the sum of the ER+ and ER-
risks. The AUC for using subtype-specific risks from the fully-adjusted models to
predict overall breast cancer risk based on FDA in the BCAC data is 0.652. This risk
discrimination is similar to what we found in the fully-adjusted BPC3 model with 86
SNPs, which had an AUC of 0.654.
Having built the subtype-specific absolute risk models, we projected absolute risk
in ages 30-70 for 2,493 controls with no missing data to estimate the distribution of
risk in the population for each subtype based on the fully-adjusted model. Figure 4.6
shows the distribution of predicted risks by subtype, along with the proportion of the
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Figure 4.5: ROC Plot for Overall Breast Cancer Risk, Defined as the Sum of ER+ and
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population that exceeds certain referent thresholds of risk. Table 4.8 shows the risk
stratification provided by the subtype-specific models, giving the average predicted
risks within deciles of risk as compared to the average absolute risk in SEER and
compared to the average risk for those with and without family history. From an
average SEER risk of 7.2% in ages 30-70, the fully-adjusted model for ER+ stratifies
risk ranging from average risk of 2.4% to 17.5% in the lowest and highest deciles of
risk respectively. The ER- model stratifies risk far less, ranging from 0.8% to 3.7%
average risk in the lower and upper deciles of risk, compared to an average SEER risk
of 1.8%. Family history alone goes a long way toward that risk stratification, with an
average risk of 1.7% for those with no family history and 2.7% for those with family
history. The overall risks presented in Table 4.8 are based on the sum of ER+ and
ER- risks and result in substantial risk stratification beyond that of family history
alone.
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Figure 4.6: Distribution of Absolute Risk of Breast Cancer for Ages 30-70 by Estrogen
Receptor Status, and the Proportions of the Population with Risk Above Specified
Risk Thresholds
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Table 4.8: Average Absolute Risk by Risk Decile for ER Subtypes and Overall Breast
Cancer in Ages 30-70
ER+ ER- Overall
SEER 7.2 1.8 8.9
Fh = No 6.7 1.7 8.4
Fh = Yes 10.7 2.7 13.4
Risk Decile Full Model Genes Covs Full Model Genes Covs Full Model Genes Covs
1 2.4 2.9 4.2 0.8 0.9 1.2 3.2 3.9 5.4
2 3.4 3.9 5.1 1.0 1.2 1.4 4.5 5.2 6.6
3 4.2 4.6 5.7 1.2 1.3 1.5 5.5 6.1 7.2
4 5.0 5.3 6.2 1.4 1.5 1.6 6.5 6.8 7.8
5 5.8 6.0 6.7 1.5 1.6 1.7 7.4 7.7 8.5
6 6.6 6.8 7.4 1.7 1.8 1.8 8.4 8.6 9.2
7 7.6 7.6 8.2 1.9 2.0 2.0 9.5 9.6 10.1
8 9.0 8.7 9.1 2.2 2.2 2.1 11.2 10.8 11.1
9 11.2 10.4 10.2 2.6 2.5 2.3 13.7 12.8 12.5
10 17.5 14.4 13.2 3.7 3.2 3.0 20.8 17.4 16.0
Fh = Family History
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4.2.4 Conclusions and Future Work
We demonstrated the utility of the methods we developed for building subtype-specific
absolute risk models by applying those methods in a real data analysis setting to the
BCAC data. We showed how subtype specific absolute risk models can be used to
project distributions of risk for each subtype in the population. We found that our
absolute risk model for ER+ breast cancer provides substantial risk stratification and
thus could be used to target preventative treatments, such as tamoxifen, to women at
high risk of ER+ breast cancer. Due to the low rate of ER- breast cancer and a lack
of strong known risk factors, our absolute risk model currently produces only modest
stratification of risk for ER- breast cancer.
In the future we plan to build off this work and continue to improve the subtype-
specific absolute risk models defined by ER status. The absolute risk models we have
presented are currently calibrated to the SEER rate for overall breast cancer, with
the marginal subtype-specific rates obtained by reweighting according to stratified
estimates of the subtype proportions observed in the data. In the future, we plan to
instead calibrate directly to the ER stratified rates available in SEER. This requires
thinking carefully about how to handle the “ER unknown” SEER rate as improper
treatment of this missing ER data can bias results. We plan to use ER+ and ER- rates
that correct for the missing ER rate in SEER through a simple published imputation
method that accounts for age and calendar year (Anderson et al., 2011).
Additionally, we plan to incorporate survey data, perhaps from the National
Health and Nutrition Examination survey (NHANES), in estimation of the attributable
risk component of the absolute risk model. Currently, we have estimated the at-
tributable risk for each subtype from cases of that subtype for which there is no
missing covariate data, thus basing the estimate on a relatively small amount of data.
Even if that criteria were met by large number observations in BCAC, it is still better
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to base our estimates of attributable risk on the covariate distribution from NHANES
as it is likely to be more representative of the US population than the distribution in
the diverse collection of case-control studies in BCAC. Similarly, we also plan to use
the covariate distribution from NHANES to specify the set of risk profiles for which
to predict risk, which should result in projected risk distributions that are more rep-
resentative of the US population. Additionally, we will incorporate risks of competing
mortality into the model.
We plan to use the BCAC data to build absolute risk models for subtypes that
are defined by progesterone receptor (PR) status and human epidermal growth fac-
tor receptor 2 (HER2) status as well as ER status. HER2 is an important tumor
characteristic for defining breast cancer subtypes as it is used to guide therapy and
as a prognostic indicator (Althuis et al., 2004). HER2+ tumors are often associated
with more aggressive behavior and worse prognosis than HER2- tumors (Jardines
et al., 2005; Burstein, 2005). Treatment by trastuzumab, or Herceptin, is available
for HER2+ breast cancers but provides no clinical benefit in HER2-negative breast
cancers (Burstein, 2005). Studies of risk factors for breast cancer subtypes defined
by HER2 suggest that the risk factors for HER2+ and HER2- tumor types differ as
well (Balsari et al., 2003; Yang et al., 2007, 2011b). Given this eterogeneity in risk
factors, treatment, and prognosis, an absolute risk model that incorporates HER2 will
provide useful information for projecting population risks for these clinically relevant
subtypes.
As part of our future work with subtypes defined jointly by ER, PR, and HER2,
we plan to develop an absolute risk model for the ER-, PR-, and HER2- subtype,
commonly referred to as triple negative breast cancer. Though this subtype is rare,
it is clinically relevant due to its biological aggressiveness, lack of treatment options
beyond chemotherapy, and poor survival outcomes (Bosch et al., 2010; Cleator et al.,
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2007). Women with triple negative breast cancers have worse survival relative to
those with other breast cancer subtypes, with a 5-year survival of 77% for the triple
negative subtype as compared to 93% for other breast cancers (Bauer et al., 2007).
Risk factors for the triple negative subtype have not been well-established, in part
because studies may be underpowered to detect associations from small numbers of
triple negative cases (Schneider et al., 2008).
The reparametrized multinomial method, which allows cases with missing tumor
characteristics or from hospital-based studies to be included in estimation of the haz-
ard ratios, will be vital to building such absolute risk models in the BCAC data as
there is a substantial amount of missing data in the PR and HER2 tumor characteris-
tics. The methods we developed for estimating subtype-specific baseline hazard rates
will be necessary in this setting, as SEER currently has little data on breast cancer
incidence rates stratified by HER2 status. We also plan to validate all absolute risk
models that we develop in independent data.
4.3 Supplemental Tables
136
Supplemental Table 4.1: Percent Completeness of Covariates by Case-Control Status and Study
in BPC3
Overall CPS2 EPIC MCCS MEC
Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls
Total 17176 19860 2558 3215 4154 5166 930 765 521 570
Family History 64.3 65.3 97.8 98.7 36.8 29.9 47.6 54.4 89.3 94.4
Menarche 97.8 98.3 98.6 98.9 95.5 96.7 99.8 99.6 99.2 99.8
Parity 97.6 97.7 98.1 98.3 92.6 92.6 100 100 99.0 99.5
Age at First Birth 95.8 91.4 97.7 98.0 95.3 77.4 99.9 100 99.0 98.6
Age at Menopause 87.2 87.6 98.0 98.4 66.2 70.1 86.6 82.7 97.3 98.6
Height 99.7 99.7 99.4 99.4 100 100 100 99.9 99.8 100
Body Mass Index 99.1 98.9 98.9 99.0 100 100 100 99.9 99.8 100
Menopause Status 94.4 94.6 98.5 98.8 82.7 84.3 96.0 100 97.3 98.4
HRT Use: Ever 80.5 80.2 23.9 26.4 75.4 78.5 98.8 99.6 96.7 98.4
HRT Use: Ever E 61.3 60.9 23.2 25.6 44.6 53.8 0 0 95.6 96.5
HRT Use: Ever C 63.6 62.2 23.2 25.6 54.0 59.0 0 0 95.6 96.5
HRT Use: Current 63.0 59.1 0.0 0.0 75.3 68.9 0 0 0 0
Alcohol Use 97.7 97.1 94.5 92.8 100 99.9 100 100 95.8 97.7
Smoking Status 98.9 99.0 98.6 98.9 98.1 98.2 100 100 99.0 99.5
NHS PLCO WHI WHS
Cases Controls Cases Controls Cases Controls Cases Controls
Total 1782 3148 790 982 5772 5349 669 665
Family History 99.3 99.6 99.0 99.5 50.5 47.2 96.7 98.2
Menarche 99.2 99.7 100 99.7 97.6 97.8 100 100
Parity 100 100 100 99.8 99.2 99.6 100 100
Age at First Birth 100 100 99.7 99.7 92.1 91.2 99.9 100
Age at Menopause 90.0 91.3 98.9 99.2 94.9 94.7 81.8 77.9
Height 99.9 99.9 99.9 99.7 99.5 99.4 99.4 98.8
Body Mass Index 95.7 96.0 99.6 99.4 99.3 99.2 99.3 98.0
Menopause Status 97.8 97.4 98.9 99.2 100 100 85.2 81.4
HRT Use: Ever 81.5 86.9 99.6 99.2 100 100 95.5 95.8
HRT Use: Ever E 82.1 72.7 0 0 100 100 52.0 45.4
HRT Use: Ever C 82.1 72.7 0 0 100 100 52.0 45.4
HRT Use: Current 63.6 59.6 99.0 97.8 100 100 0 0
Alcohol Use 92.1 93.4 92.7 90.0 99.5 99.6 100 100
Smoking Status 99.9 99.7 100.0 99.9 98.7 99.0 100 99.8
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Supplemental Table 4.2: Hazard Ratio Estimates for Fully-Adjusted Model for Overall
Breast Cancer with PGRS for Empirical Genotype Data on 24 SNPs in BPC3
Hazard Ratio (95% Confidence Interval)
PGRS category=1 1 –
PGRS category=2 1.19 (0.76, 1.88)
PGRS category=3 1.33 (0.84, 2.1)
PGRS category=4 1.43 (0.91, 2.25)
PGRS category=5 1.58 (1, 2.48)
PGRS category=6 1.66 (1.06, 2.6)
PGRS category=7 1.78 (1.14, 2.79)
PGRS category=8 2.05 (1.31, 3.21)
PGRS category=9 2.26 (1.45, 3.51)
PGRS decile=10 2.80 (1.82, 4.33)
Family History = No 1 –
Family History = Yes 1.41 (1.02, 1.94)
Menarche category=1 1 –
Menarche category=2 1.07 (0.53, 2.17)
Menarche category=3 0.96 (0.67, 1.38)
Menarche category=4 0.92 (0.65, 1.31)
Menarche category=5 0.90 (0.61, 1.32)
Menarche category=6 0.91 (0.59, 1.41)
Continued on next page...
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Supplemental Table 4.2 – continued from previous page
Hazard Ratios (95% Confidence Interval)
Menarche category=7 0.86 (0.54, 1.37)
Parity = 0 1 –
Parity = 1 0.84 (0.52, 1.37)
Parity = 2 0.76 (0.49, 1.2)
Parity = 3 0.75 (0.47, 1.18)
Parity = 4 0.72 (0.45, 1.15)
AFFTB category=1 1 –
AFFTB category=2 1.07 (0.69, 1.65)
AFFTB category=3 1.05 (0.65, 1.67)
AFFTB category=4 1.02 (0.68, 1.55)
AFFTB category=5 1.23 (0.78, 1.93)
AFFTB category=6 1.40 (0.87, 2.25)
AFFTB category=7 1.37 (0.85, 2.21)
AFFTB category=8 1.43 (0.76, 2.69)
AFFTB category=9 1.34 (0.58, 3.08)
AgeMeno category=1 1 –
AgeMeno category=2 0.99 (0.64, 1.55)
AgeMeno category=3 0.99 (0.63, 1.56)
AgeMeno category=4 1.06 (0.66, 1.72)
Continued on next page...
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Supplemental Table 4.2 – continued from previous page
Hazard Ratios (95% Confidence Interval)
AgeMeno category=5 1.15 (0.75, 1.77)
AgeMeno category=6 1.17 (0.72, 1.9)
AgeMeno category=7 1.24 (0.79, 1.95)
AgeMeno category=8 1.30 (0.79, 2.16)
AgeMeno category=9 1.29 (0.8, 2.07)
AgeMeno category=10 1.12 (0.69, 1.84)
Height category=1 1 –
Height category=2 1.12 (0.74, 1.71)
Height category=3 1.14 (0.74, 1.75)
Height category=4 1.17 (0.76, 1.81)
Height category=5 1.10 (0.72, 1.67)
Height category=6 1.23 (0.8, 1.89)
Height category=7 1.20 (0.78, 1.86)
Height category=8 1.31 (0.85, 2.01)
Height category=9 1.22 (0.79, 1.88)
Height category=10 1.31 (0.85, 2.02)
BMI category=1 1 –
BMI category=2 1.06 (0.59, 1.92)
BMI category=3 0.91 (0.49, 1.69)
Continued on next page...
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Supplemental Table 4.2 – continued from previous page
Hazard Ratios (95% Confidence Interval)
BMI category=4 0.99 (0.53, 1.86)
BMI category=5 0.89 (0.46, 1.71)
BMI category=6 1.09 (0.55, 2.17)
BMI category=7 1.00 (0.49, 2.02)
BMI category=8 0.98 (0.48, 2)
BMI category=9 0.95 (0.46, 1.96)
BMI category=10 1.06 (0.51, 2.21)
PreMeno 1 –
PostMeno HRT=Never 0.59 (0.32, 1.11)
PostMeno Ever HRT 0.68 (0.37, 1.27)
PostMeno Ever E HRT 1.02 (0.7, 1.49)
PostMeno Ever EP HRT 1.28 (0.88, 1.87)
PostMeno HRT=Current 1.24 (0.85, 1.8)
Alcohol category=1 1 –
Alcohol category=2 0.96 (0.65, 1.42)
Alcohol category=3 1.02 (0.68, 1.53)
Alcohol category=4 1.06 (0.72, 1.57)
Alcohol category=5 0.98 (0.66, 1.45)
Alcohol category=6 1.07 (0.72, 1.59)
Continued on next page...
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Supplemental Table 4.2 – continued from previous page
Hazard Ratios (95% Confidence Interval)
Alcohol category=7 1.18 (0.79, 1.75)
Alcohol category=8 1.25 (0.84, 1.86)
Smoking = Never 1 –
Smoking = Former 1.08 (0.79, 1.47)
Smoking = Current 1.15 (0.8, 1.67)
(BMI category)*(PreMeno) 1 –
(BMI category=2)*(PostMeno HRT=Never) 1.00 (0.5, 2)
(BMI category=3)*(PostMeno HRT=Never) 1.21 (0.6, 2.46)
(BMI category=4)*(PostMeno HRT=Never) 1.20 (0.59, 2.44)
(BMI category=5)*(PostMeno HRT=Never) 1.37 (0.66, 2.83)
(BMI category=6)*(PostMeno HRT=Never) 1.05 (0.49, 2.23)
(BMI category=7)*(PostMeno HRT=Never) 1.33 (0.62, 2.87)
(BMI category=8)*(PostMeno HRT=Never) 1.44 (0.66, 3.12)
(BMI category=9)*(PostMeno HRT=Never) 1.56 (0.71, 3.43)
(BMI category=10)*(PostMeno HRT=Never) 1.46 (0.66, 3.23)
(BMI category=2)*(PostMeno HRT=Ever) 0.96 (0.5, 1.82)
(BMI category=3)*(PostMeno HRT=Ever) 1.11 (0.57, 2.17)
(BMI category=4)*(PostMeno HRT=Ever) 1.12 (0.57, 2.2)
(BMI category=5)*(PostMeno HRT=Ever) 1.18 (0.58, 2.37)
Continued on next page...
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Supplemental Table 4.2 – continued from previous page
Hazard Ratios (95% Confidence Interval)
(BMI category=6)*(PostMeno HRT=Ever) 1.06 (0.51, 2.19)
(BMI category=7)*(PostMeno HRT=Ever) 1.13 (0.54, 2.4)
(BMI category=8)*(PostMeno HRT=Ever) 1.27 (0.6, 2.71)
(BMI category=9)*(PostMeno HRT=Ever) 1.27 (0.59, 2.74)
(BMI category=10)*(PostMeno HRT=Ever) 1.25 (0.57, 2.74)
Supplemental Table 4.3: Hazard Ratios (HR) and 95% Confidence Intervals (CI) for
SNPs in Fully-Adjusted Models of ER+ and ER- Breast Cancer, with Results from
Full Data Analysis (FDA) and Complete Case Analysis (CCA)
ER+ ER-
FDA CCA FDA CCA
SNP HR (CI) HR (CI) HR (CI) HR (CI)
rs78540526 1.38 (1.04, 1.83) 1.38 (1.02, 1.86) 0.79 (0.55, 1.15) 0.74 (0.39, 1.42)
rs75915166 1.26 (1.05, 1.5) 1.27 (1.04, 1.56) 1.31 (1.08, 1.59) 0.9 (0.64, 1.26)
rs554219 1.23 (1.15, 1.32) 1.24 (1.15, 1.34) 1.19 (1.1, 1.29) 1.23 (1.08, 1.39)
rs7726159 1.2 (1, 1.45) 1.23 (1.01, 1.5) 1.09 (0.89, 1.35) 1.27 (0.93, 1.73)
rs10069690 1.18 (1.06, 1.33) 1.2 (1.05, 1.36) 1.07 (0.94, 1.22) 0.97 (0.79, 1.19)
rs2736108 1.15 (1.09, 1.21) 1.16 (1.1, 1.23) 1.06 (1, 1.13) 1.03 (0.94, 1.12)
rs2588809 1.14 (1.06, 1.23) 1.16 (1.04, 1.29) 1.02 (0.94, 1.11) 1.15 (0.98, 1.36)
Continued on next page...
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Supplemental Table 4.3 – continued from previous page
ER+ ER-
FDA CCA FDA CCA
SNP HR (CI) HR (CI) HR (CI) HR (CI)
rs999737 1.13 (1.03, 1.24) 1.15 (1.08, 1.23) 1.13 (1.02, 1.25) 1.05 (0.95, 1.16)
rs10759243 1.13 (1.07, 1.19) 1.15 (1.04, 1.27) 1.09 (1.03, 1.16) 1.1 (0.95, 1.27)
rs865686 1.13 (1.03, 1.22) 1.11 (1.05, 1.18) 1.13 (1.03, 1.24) 0.95 (0.87, 1.04)
rs2981579 1.11 (1.05, 1.18) 1.11 (1.04, 1.18) 1.05 (0.98, 1.13) 1.03 (0.93, 1.13)
rs11199914 1.11 (1.05, 1.17) 1.1 (1.01, 1.2) 1.02 (0.95, 1.08) 1.04 (0.91, 1.2)
rs7072776 1.11 (0.97, 1.26) 1.1 (0.98, 1.23) 1.05 (0.9, 1.22) 1.2 (1.02, 1.42)
rs11814448 1.1 (1.04, 1.16) 1.09 (1, 1.2) 1.03 (0.97, 1.09) 1.1 (0.95, 1.26)
rs13387042 1.1 (1.01, 1.19) 1.09 (1.02, 1.17) 1.1 (1.01, 1.2) 1 (0.9, 1.11)
rs16857609 1.09 (1.04, 1.15) 1.09 (1.02, 1.16) 1.02 (0.96, 1.08) 1 (0.91, 1.1)
rs11552449 1.09 (1.03, 1.16) 1.09 (1.02, 1.16) 1.14 (1.07, 1.22) 1.09 (0.99, 1.19)
rs11249433 1.09 (1.04, 1.14) 1.09 (1.02, 1.16) 1.06 (1.01, 1.12) 0.99 (0.9, 1.09)
rs1045485 1.09 (0.98, 1.2) 1.08 (1.01, 1.16) 1.12 (1.01, 1.25) 0.96 (0.87, 1.07)
rs4973768 1.08 (1.02, 1.14) 1.08 (1.02, 1.14) 1.05 (0.98, 1.11) 1.05 (0.96, 1.14)
rs10941679 1.08 (1.02, 1.14) 1.08 (1.01, 1.16) 1.02 (0.96, 1.09) 1.14 (1.02, 1.27)
rs889312 1.07 (1.02, 1.13) 1.08 (1.01, 1.15) 1.05 (0.99, 1.11) 0.96 (0.87, 1.07)
rs12662670 1.07 (1.01, 1.14) 1.08 (1.01, 1.15) 1.11 (1.04, 1.19) 1.21 (1.09, 1.34)
rs2046210 1.07 (1.01, 1.13) 1.08 (1.02, 1.14) 1.03 (0.97, 1.09) 1.02 (0.94, 1.11)
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SNP HR (CI) HR (CI) HR (CI) HR (CI)
rs13281615 1.06 (1.01, 1.12) 1.08 (1.01, 1.14) 1.03 (0.98, 1.09) 0.95 (0.87, 1.05)
rs1011970 1.06 (1, 1.13) 1.07 (1.01, 1.13) 1.08 (1.01, 1.16) 1.12 (1.03, 1.23)
rs2380205 1.06 (1.01, 1.12) 1.07 (1.01, 1.14) 1.03 (0.97, 1.1) 0.96 (0.87, 1.05)
rs10995190 1.06 (1, 1.13) 1.07 (1.01, 1.13) 1.02 (0.95, 1.09) 1.02 (0.94, 1.12)
rs704010 1.06 (1.01, 1.12) 1.07 (1, 1.14) 1.01 (0.96, 1.07) 1.03 (0.94, 1.14)
rs3817198 1.06 (1.01, 1.11) 1.07 (1.01, 1.13) 1.1 (1.04, 1.16) 0.97 (0.89, 1.06)
rs10771399 1.06 (1.01, 1.11) 1.06 (1, 1.12) 1.06 (1, 1.12) 1.07 (0.98, 1.16)
rs1292011 1.06 (1.01, 1.11) 1.06 (1, 1.12) 1 (0.95, 1.06) 1.05 (0.96, 1.14)
rs3803662 1.05 (1, 1.11) 1.06 (1, 1.12) 1.02 (0.96, 1.08) 1.04 (0.95, 1.14)
rs6504950 1.05 (1, 1.1) 1.06 (0.91, 1.23) 1.02 (0.97, 1.08) 1.12 (0.89, 1.41)
rs8170 1.05 (0.99, 1.11) 1.05 (0.99, 1.13) 1.03 (0.96, 1.1) 1.13 (1.02, 1.25)
rs2363956 1.03 (0.98, 1.09) 1.05 (0.96, 1.15) 1.03 (0.98, 1.09) 0.84 (0.74, 0.97)
rs2823093 1.03 (0.98, 1.08) 1.04 (0.98, 1.1) 1.05 (0.99, 1.11) 1.06 (0.97, 1.16)
rs17879961 1.03 (0.98, 1.08) 1.03 (0.95, 1.12) 0.95 (0.9, 1.01) 0.96 (0.84, 1.08)
rs616488 1.01 (0.94, 1.09) 1.02 (0.96, 1.08) 0.97 (0.89, 1.05) 1.04 (0.95, 1.14)
rs4849887 0.99 (0.94, 1.04) 1.02 (0.95, 1.08) 1.05 (0.99, 1.11) 0.88 (0.79, 0.97)
rs2016394 0.99 (0.93, 1.05) 1.01 (0.96, 1.07) 0.93 (0.87, 0.99) 1 (0.92, 1.1)
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rs1550623 0.98 (0.91, 1.06) 1 (0.74, 1.37) 0.98 (0.9, 1.06) 0.63 (0.42, 0.94)
rs6762644 0.98 (0.91, 1.06) 0.99 (0.82, 1.19) 0.94 (0.86, 1.03) 0.79 (0.58, 1.07)
rs12493607 0.97 (0.92, 1.02) 0.99 (0.93, 1.05) 0.97 (0.92, 1.03) 1.07 (0.98, 1.17)
rs9790517 0.97 (0.92, 1.02) 0.99 (0.93, 1.04) 0.95 (0.9, 1.01) 0.95 (0.87, 1.05)
rs6828523 0.97 (0.92, 1.02) 0.97 (0.91, 1.04) 0.98 (0.92, 1.04) 0.94 (0.85, 1.04)
rs10472076 0.97 (0.91, 1.02) 0.97 (0.91, 1.03) 1.06 (1, 1.13) 0.98 (0.89, 1.08)
rs1353747 0.96 (0.92, 1.01) 0.97 (0.9, 1.04) 0.95 (0.9, 1.01) 0.85 (0.76, 0.95)
rs1432679 0.96 (0.91, 1.02) 0.97 (0.91, 1.03) 1.01 (0.95, 1.08) 0.96 (0.88, 1.05)
rs11242675 0.96 (0.88, 1.05) 0.97 (0.91, 1.03) 0.9 (0.82, 1) 1.03 (0.94, 1.13)
rs204247 0.96 (0.9, 1.02) 0.96 (0.9, 1.03) 0.97 (0.91, 1.04) 1.07 (0.97, 1.18)
rs17529111 0.96 (0.89, 1.03) 0.96 (0.9, 1.02) 0.94 (0.87, 1.02) 0.96 (0.87, 1.06)
rs720475 0.95 (0.89, 1.02) 0.96 (0.9, 1.01) 0.99 (0.92, 1.07) 0.87 (0.8, 0.96)
rs9693444 0.95 (0.73, 1.24) 0.95 (0.9, 1.01) 0.91 (0.68, 1.21) 0.94 (0.86, 1.03)
rs6472903 0.95 (0.9, 1.01) 0.95 (0.88, 1.04) 0.95 (0.89, 1.01) 0.93 (0.81, 1.06)
rs2943559 0.95 (0.8, 1.12) 0.95 (0.9, 1.01) 0.93 (0.77, 1.12) 0.86 (0.79, 0.94)
rs11780156 0.94 (0.88, 1.01) 0.95 (0.89, 1.01) 0.92 (0.85, 0.99) 0.9 (0.82, 0.99)
rs7904519 0.94 (0.89, 0.99) 0.94 (0.87, 1.03) 0.9 (0.85, 0.96) 1.05 (0.92, 1.19)
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rs3903072 0.94 (0.89, 0.99) 0.94 (0.88, 1.02) 0.93 (0.88, 0.99) 1.04 (0.93, 1.18)
rs11820646 0.94 (0.89, 0.99) 0.92 (0.87, 0.98) 0.86 (0.81, 0.92) 0.89 (0.81, 0.98)
rs12422552 0.93 (0.89, 0.98) 0.92 (0.87, 0.97) 0.96 (0.91, 1.02) 0.91 (0.83, 0.99)
rs17356907 0.93 (0.88, 0.98) 0.92 (0.86, 0.98) 0.87 (0.82, 0.93) 0.93 (0.84, 1.02)
rs11571833 0.92 (0.88, 0.97) 0.92 (0.86, 0.97) 0.97 (0.91, 1.02) 0.88 (0.8, 0.96)
rs2236007 0.92 (0.87, 0.97) 0.91 (0.86, 0.97) 0.95 (0.89, 1.01) 0.98 (0.9, 1.07)
rs941764 0.92 (0.87, 0.97) 0.91 (0.86, 0.96) 0.94 (0.88, 1) 1.04 (0.95, 1.14)
rs17817449 0.92 (0.85, 0.98) 0.91 (0.82, 1) 0.93 (0.86, 1) 1.02 (0.87, 1.19)
rs13329835 0.91 (0.87, 0.97) 0.91 (0.84, 0.98) 0.99 (0.93, 1.06) 1 (0.89, 1.12)
rs527616 0.91 (0.86, 0.98) 0.9 (0.83, 0.98) 0.94 (0.87, 1.01) 0.99 (0.88, 1.12)
rs1436904 0.91 (0.87, 0.96) 0.9 (0.84, 0.96) 0.94 (0.88, 0.99) 1.1 (1, 1.22)
rs4808801 0.91 (0.85, 0.97) 0.89 (0.85, 0.95) 0.96 (0.89, 1.03) 0.97 (0.89, 1.06)
rs3760982 0.9 (0.86, 0.95) 0.88 (0.82, 0.95) 0.96 (0.9, 1.01) 1 (0.89, 1.13)
rs132390 0.9 (0.84, 0.96) 0.88 (0.83, 0.93) 0.94 (0.87, 1.01) 0.99 (0.91, 1.08)
rs6001930 0.89 (0.85, 0.94) 0.87 (0.81, 0.94) 0.95 (0.9, 1.01) 0.97 (0.86, 1.08)
rs4245739 0.87 (0.83, 0.92) 0.86 (0.79, 0.94) 0.94 (0.89, 0.99) 0.77 (0.67, 0.89)
rs6678914 0.82 (0.76, 0.89) 0.85 (0.81, 0.91) 0.79 (0.72, 0.86) 0.92 (0.84, 1)
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rs12710696 0.8 (0.76, 0.85) 0.8 (0.75, 0.85) 0.84 (0.79, 0.89) 0.83 (0.75, 0.91)
rs11075995 0.76 (0.73, 0.8) 0.74 (0.7, 0.78) 0.91 (0.86, 0.96) 0.97 (0.89, 1.06)
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